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Supplementary Table 1: Search strategy 
 
Medline Ovid  
1 exp Uterine Cervical Neoplasms/ 
2 (cervi* and (cancer* or tumor* or tumour* or neoplas* or malignan* or carcinom*)).mp.  
3 exp Cervical Intraepithelial Neoplasia/ 
4 CIN.mp.  
5 (cervi* and (intraepithel* or epithel* or dysplasia or pre-cancer* or precancer*)).mp.  
6 or/1-5 
7 exp Conization/ 
8 (conisation or conization).mp.  
9 exp Laser Therapy/ 
10 laser.mp.  
11 exp Cryotherapy/ 
12 cryotherapy.mp.  
13 cold coagulation.mp. 
14 exp Diathermy/ 
15 diatherm*.mp.  
16 cone biopsy.mp.  
17 loop.mp. 
18 LLETZ.mp.  
19 LEEP.mp.  
20 ablat*.mp.  
21 excision*.mp.  
22 transformation zone.mp.  
23 (CKC or LA or LC or CC or RD or TZ).mp.  
24 (conservative and (method* or treatment* or intervention* or management)).mp.  
25 or/7-24 
26 6 and 25 
27 exp Premature Birth/ 
28 (preterm or premature).mp.  
29 exp Infant, Low Birth Weight/ 
30 birth weight.mp.  
31 Perinatal Mortality/ 
32 perinatal mortality.mp.  
33 exp Intensive Care, Neonatal/ 
34 (neonatal and intensive care).mp. 
35 exp Fertility/ 
36 fertil*.mp.  
37 conception.mp. 
38 exp Pregnancy/ 
39 pregnancy.mp.  
40 gestation*.mp.  
41 exp Abortion, Spontaneous/ 
42 miscarriage*.mp.  
43 exp Cesarean Section/ 
44 (cesarean or caesarean).mp.  
45 exp Obstetric Labor, Premature/ 
46 exp Labor, Obstetric/ 
47 (labor or labour).mp.  
48 Fetal Membranes, Premature Rupture/ 
49 pPROM.mp.  
50 or/27-49 
51 26 and 50 
key: 
mp=title, original title, abstract, name of substance word, subject heading word 
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Embase Ovid 
 
1 exp uterine cervix tumor/ 
2 (cervi* and (cancer* or tumor* or tumour* or neoplas* or malignan* or carcinom*)).mp.  
3 uterine cervix carcinoma in situ/ 
4 CIN.mp.  
5 (cervi* and (intraepithel* or epithel* or dysplasia or pre-cancer* or precancer*)).mp.  
6 or/1-5 
7 uterine cervix conization/ 
8 (conisation or conization).mp. 
9 low level laser therapy/ 
10 laser.mp. 
11 exp cryotherapy/ 
12 cryotherapy.mp. 
13 cold coagulation.mp. 
14 diathermy/ 
15 diatherm*.mp. 






22 transformation zone.mp. 
23 (CKC or LA or LC or CC or RD or TZ).mp. 
24 (conservative and (method* or treatment* or intervention* or management)).mp.  
25 or/7-24 
26 6 and 25 
27 prematurity/ 
28 (preterm or premature).mp. 
29 exp low birth weight/ 
30 birth weight.mp. 
31 perinatal mortality/ 
32 perinatal mortality.mp. 
33 newborn intensive care/ 
34 (neonat* and intensive care).mp.  




39 exp pregnancy/ 
40 pregnancy.mp. 
41 gestation*.mp. 
42 spontaneous abortion/ 
43 miscarriage*.mp. 
44 cesarean section/ 
45 (cesarean or caesarean).mp. 
46 premature labor/ 
47 (labor or labour).mp. 
48 premature fetus membrane rupture/ 
49 pPROM.mp. 
50 or/27-49 
51 26 and 50 
key: 
mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name 
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CENTRAL  
 
#1 MeSH descriptor Uterine Cervical Neoplasms explode all trees 
#2 cervi* and (cancer* or tumor* or tumour* or neoplas* or malignan* or carcinom*) 
#3 MeSH descriptor Cervical Intraepithelial Neoplasia explode all trees 
#4 CIN 
#5 cervi* and (intraepithel* or epithel* or dysplasia or pre-cancer* or precancer*) 
#6 (#1 OR #2 OR #3 OR #4 OR #5) 
#7 MeSH descriptor Conization explode all trees 
#8 conisation or conization 
#9 MeSH descriptor Laser Therapy explode all trees 
#10 laser 
#11 MeSH descriptor Cryotherapy explode all trees 
#12 cryotherapy 
#13 cold coagulation 
#14 MeSH descriptor Diathermy explode all trees 
#15 diatherm* 






#22 transformation zone 
#23 CKC or LA or LC or CC or RD or TZ 
#24 conservative and (method* or treatment* or intervention* or management) 
#25 (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 
OR #20 OR #21 OR #22 OR #23 OR #24) 
#26 (#6 AND #25) 
#27 MeSH descriptor Premature Birth explode all trees 
#28 preterm or premature 
#29 MeSH descriptor Infant, Low Birth Weight explode all trees 
#30 birth weight 
#31 MeSH descriptor Perinatal Mortality explode all trees 
#32 perinatal mortality 
#33 MeSH descriptor Intensive Care, Neonatal explode all trees 
#34 neonat* and (intensive care) 
#35 MeSH descriptor Fertility explode all trees 
#36 fertil* 
#37 conception 
#38 MeSH descriptor Pregnancy explode all trees 
#39 pregnancy 
#40 gestation* 
#41 MeSH descriptor Abortion, Spontaneous explode all trees 
#42 miscarriage* 
#43 MeSH descriptor Cesarean Section explode all trees 
#44 cesarean or caesarean 
#45 MeSH descriptor Obstetric Labor, Premature explode all trees 
#46 MeSH descriptor Labor, Obstetric explode all trees 
#47 labor or labour 
#48 MeSH descriptor Fetal Membranes, Premature Rupture explode all trees 
#49 pPROM 
#50 (#27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR 
#39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49) 
#51 (#26 AND #50) 
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ABSTRACT 
Objective: To assess the effect of treatment for CIN on obstetric outcomes and to correlate 
this to the cone depth and comparison group used. 
Methods 
Design: Systematic review and meta-analysis 
Data Sources: CENTRAL, MEDLINE, EMBASE from 1948 to April 2016. 
Eligibility Criteria: Studies assessing obstetric outcomes in women with or without a previous 
local cervical treatment. 
Data Extraction & Synthesis: Independent reviewers extracted the data and performed 
quality assessment using the Newcastle-Ottawa criteria. Studies were classified according to 
method and obstetric endpoint. Pooled risk ratios (RR) were calculated using a random-
effect model and inverse variance. Inter-study heterogeneity was assessed with I
2 
statistics. 
Main outcomes and measures: Obstetric outcomes; preterm birth (PTB) (spontaneous and 
threatened), premature rupture of the membranes (pPROM), chorioamnionitis, mode of 
delivery, length of labour, induction of delivery, oxytocin use, haemorrhage, analgesia, 
cervical cerclage & cervical stenosis. Neonatal outcomes; low birth weight (LBW), neonatal 
intensive care unit (NICU) admission, stillbirth, APGAR scores and perinatal mortality. 
Results: Seventy-one studies were included (6338982 participants: 65082 treated-6292563 
untreated). Treatment significantly increased the risk of overall (<37weeks)(10.7 v 5.4%, 
RR=1.78[1.60 to 1.98]), severe (<34/32weeks)(3.5 v 1.4%, RR=2.40[1.92 to 2.99]) and 
extreme (<30/28weeks)(1.0 v 0.3%, RR=2.54[1.77 to 3.63]) PTB. The magnitude of the effect 
was higher for techniques removing or ablating more tissue (<37weeks: CKC (RR=2.70[2.14 
to 3.40]), LC (RR=2.11[1.26 to 3.54)], excision not otherwise specified (NOS) (RR=2.02[1.60 to 
2.55]), LLETZ (RR=1.56[1.36 to 1.79]), ablation NOS (RR=1.46[1.27 to 1.66]). The risk of PTB 
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 3 
increased with repeat treatment (13.2 v 4.1%, RR=3.78[2.65 to 5.39]) and with increasing 
cone depth (≤12/10mm: 7.1 v 3.4%, RR=1.54[1.09 to 2.18]; ≥10/12mm: 9.8 v 3.4%, 
RR=1.93[1.62 to 2.31]; ≥15/17mm: 10.1 v 3.4%, RR=2.77[1.95 to 3.93]; ≥20mm: 10.2 v 3.4%, 
RR=4.91[2.06 to 11.68]), when compared to no treatment. The choice of comparison group 
affected the magnitude of effect that was higher for external, followed by internal 
comparators and ultimately women with disease but no treatment. The pregnancies of 
women with disease but no treatment and the pregnancies of treated women before 
treatment had higher risk of PTB than the general population (5.9 v 5.6%, RR=1.24[1.14 to 
1.35]). Spontaneous PTB, pPROM, chorioamnionitis, LBW, NICU admission and perinatal 
mortality were also significantly increased after treatment. 
Conclusions: Women with CIN have a higher baseline risk for prematurity. Excisional and 
ablative treatment further increases that risk. The frequency and severity of adverse 











































































Confidential: For Review Only
 4 
INTRODUCTION 
The mean age of women undergoing local treatment for cervical preinvasive cervical disease 
(cervical intra-epithelial neoplasia; CIN) is similar to the age of women having their first child. 
Local cervical treatment has been correlated to an increased risk of preterm birth, perinatal 
morbidity and mortality in a subsequent pregnancy (1-6). The underlying mechanism is 
unclear; hypotheses include immunomodulation relating to HPV infection affecting 
parturition pathways, and acquired ‘mechanical weakness’ secondary to loss of cervical 
tissue(7). 
In England alone in 2013–14, 3.6 million women aged between 25 and 64 
years attended for cervical screening and over 23 800 cervical procedures 
were carried out (8), the vast majority in an outpatient setting.  In contrast in 
the US, there are approximately 400,000 cases of pre-invasive disease per 
year (9). The regulations in colposcopy are more liberal leading to wide 
variation in clinical practice. In Germany, treatment for CIN is still commonly 
performed with the cold knife under general analgesia (10). The long-term 
sequelae of treatment remains therefore an important international issue to 
both health care professionals and women whatever the clinical setting.   
Since the first systematic review of the reproductive risk associated with treatment almost a 
decade ago (1), more than 50 observational studies have been published confirming (11, 12) 
or disputing these associations (13, 14); some of these reporting data from large population-
based datasets. Individual attempts to synthesize parts of this rapidly evolving evidence base 
in small systematic reviews and meta-analyses reached contradictory conclusions (1-4, 15-
18) and initiated debates and confusion within the scientific community (2, 15-18). Whether 
these discrepancies were due to questionable quality of some of these primary and 
secondary studies or differences in the explored comparisons (4, 15-17), the subject is open 
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to a definitive comprehensive high quality synthesis of the existing evidence that will be 
highly informative to women, clinicians and policy makers. 
Media publicity has heightened public awareness that treatment for cervical precancer is 
associated with an increased reproductive morbidity. There has been a substantial increase 
in enquiries from patients and clinicians on the risks associated with different treatment 
techniques and cone depths (19, 20), and as to how this risk may be managed and 
prevented. With a rapidly evolving evidence base and lack of a robust synthesis of the 
published literature, these questions are becoming increasingly difficult to answer.  
The aim of this systematic review and meta-analysis is to explore the impact that treatment 
for cervical pre-invasive and early invasive disease has on obstetric outcomes and to explore 
how this risk may be modified by the cone depth and comparison group. 
 
MATERIALS AND METHODS  
Inclusion Criteria and Outcomes 
We included all studies reporting on obstetric outcomes (more than 24 weeks of gestation) 
in women with a previous local cervical treatment for CIN or early invasive cervical cancer as 
compared to women without treatment. Studies reporting on the outcomes following two 
or more treatment were also included. The interventions included any type of treatment, 
either excisional (cold knife conisation [CKC]; laser conisation (LC); needle excision of the 
transformation zone [NETZ], also known as (aka) straight wire excision [SWETZ]; large loop 
excision of the transformation zone [LLETZ], aka loop electrosurgical excisional procedure 
[LEEP]) or ablative (laser ablation [LA]; radical diathermy [RD]; cold coagulation [CC]; 
cryotherapy [CT]). In studies that reported on the impact of several treatment techniques, 
we extracted data for each specific method, where possible. If the outcomes were not 
reported separately for each technique, we analysed the intervention under broader terms, 
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i.e. excisional treatment not otherwise specified (NOS), ablative treatment NOS and 
treatment NOS.  
Women were included irrespective of the grade of the lesion for both squamous and 
glandular intra-epithelial neoplasia. We excluded studies that did not include an untreated 
reference population, compared different treatment techniques without an untreated 
control, or compared outcomes for treatments performed during pregnancy. 
Studies were included irrespective of the type of untreated reference population that could 
have been drawn from one of the following sources: a) External group from general 
population that was mostly matched or adjusted for confounders; b) Internal group with 
self-matching of the pregnancies for the same women before and after treatment; c) 
Internal group with the pre-treatment pregnancies of those women that also delivered 
before the treatment; d) Women attending colposcopy with or without CIN/biopsy but no 
treatment; e) Women with high-grade disease but no treatment (high-grade squamous 
intra-epithelial lesion [HSIL]).  
We assessed obstetric outcomes of pregnancies progressing beyond 24 weeks of gestation. 
We examined both maternal and neonatal outcomes. The maternal outcomes included 
overall (<37 weeks of gestation), severe (<34/32 weeks) and extreme (<30/28 weeks) 
prematurity (preterm birth [PTB]); PTB in singleton and multiple pregnancies; PTB in 
nulliparous and parous women; PTB in single and repeat cones; PTB for different cone 
depths and volumes; PTB for different comparison groups; overall (<37 weeks of gestation), 
severe (<34/32 weeks) and extreme (<30/28 weeks) spontaneous prematurity (sPTB)(ie. non 
iatrogenic); threatened PTB; premature rupture of the membranes (pPROM); 
chorioamnionitis; mode of delivery (caesarean section, instrumental deliveries); length of 
labour (precipitous, prolonged); induction of labour or oxytocin use; haemorrhage 
(antepartum, postpartum); analgesia (epidural, pethidine, NOS); cervical stenosis; cervical 
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cerclage. The neonatal outcomes included: low birth weight (LBW) at <2500g, <2000g, 
<1500g and <1000g; neonatal intensive unit (NICU) admission; perinatal mortality; stillbirth; 
Apgar score. In cases of heterogeneity in the cut-offs used for cone depth and prematurity 
classification, these were grouped together when possible (ie. 32/34 weeks to include both 
cut-offs, 10/12mm cone depth to include studies grouping at both these cut-offs including or 
not the values equal to these numbers).  
Literature search, Data extraction and Risk of bias 
We searched three electronic databases (CENTRAL, MEDLINE and EMBASE) and targeted 
reports published between 1948 and April 2016. We used keywords such as ‘cervical 
intraepithelial neoplasia (CIN)’, ‘cervical cancer’, ‘LLETZ or LEEP’, ‘conisation’, ‘excision’, 
‘pregnancy’, ‘obstetric’, ‘preterm birth’, ‘prematurity’. The full strategy is included in a 
supplementary file (Supplementary Table 1). In an attempt to identify any articles missed by 
the initial search or any unpublished data, we hand searched the references of the retrieved 
articles and meta-analyses and the proceedings of relevant conferences. There was no 
language restriction. 
From each study, we extracted data on the study design and setting, the study population, 
the interventions examined, the comparison group, the quality of the data and risk of bias 
and the outcomes assessed. We retrieved from each study and outcome, the number of 
events in treated and untreated women. If required, authors were contacted to obtain 
additional data if the numbers provided in the published report did not allow sufficient 
precision in the data extraction. 
We used the Newcastle-Ottawa score to formally assess the quality of non-randomised 
cohort studies(21), according to the MOOSE checklist(22). This scoring system assesses the 
a) cohort selection, b) comparability and c) assessment of outcomes, to give a maximum 
score of 9 (highest quality).  
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Two investigators (MK, AA) independently performed the literature search, assessed the 
eligibility and quality of the retrieved papers and performed the data extraction. The two 
authors then compared the results and disagreements were resolved by discussion. If 
required, a consensus was reached with the involvement of a third investigator (MA) if 
necessary. 
Data Synthesis and Assessment of heterogeneity  
We calculated the risk ratio (RR) and 95% confidence intervals (95% CI) for each reported 
outcome in the treated versus untreated women for dichotomous outcomes using the 
Cochrane Revman 5 software. We used a random-effect model and inverse variance 
weighting for all meta-analyses (23). In studies with multiple treatment groups, we 
proportionally divided the ‘shared’ comparison group into the number of treatment groups; 
we treated comparisons between each treatment group and the split comparison group as 
independent comparisons. If a study presented data for more than one comparison group, 
the external comparison group of women with or without disease was used in preference to 
internal controls. If data were not of suitable quality for meta-analysis, we reported the 
results as a narrative in the text of the review. 
We assessed inter-study heterogeneity with the Cochran Q test, by visual inspection of 
forest plots (24), by estimation of the percentage of heterogeneity between studies which 
cannot be ascribed to sampling variation (I
2 
statistic) (25), and by a formal test of the 
significance for heterogeneity(26). If there was evidence of substantial heterogeneity, the 
possible reasons for this were investigated and reported. 
We performed a series of subgroup analyses. We analysed the data separately for each 
treatment modality, in groups of ablative and excisional techniques, and as a whole 
irrespective of the type of method used. We further analysed the data according to the cone 
depth. Given the non-randomised nature of the included studies, we assessed whether the 
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choice of comparison group impacts on the risk estimate for each outcome and over-inflates 
the effect of treatment that could be partly attributed to other confounders. We therefore 
distinguished the different untreated comparison groups used across studies and performed 
subgroup analyses for the risk of PTB for each individual comparator (external; internal (self-
matching); internal (pre-treatment pregnancies); colposcopy but no treatment; HSIL but no 
treatment). Furthermore, we performed sensitivity analysis to assess the impact of the 
quality of the studies on some selected outcomes. We calculated the median score from the 
Newcastle-Ottawa scale and performed sensitivity analysis for studies that scored more than 
the median. We performed subgroup analyses based on the cohort selection in the 
Newcastle-Ottawa score (truly or somewhat representative) and the comparability of the 
groups (those that scored one or two). Finally, we performed meta-regression analysis to 
assess the impact of some factors on the risk of PTB (<37 weeks). These included the quality 
of the studies (based on the Newcastle-Ottawa score); year of study (1979-1989, 1990-1999, 
2000-2009, 2010-2015); type of treatment (excision or ablation); type of comparator 
(external, internal –pretreatment pregnancies, internal – self matching, CIN but no 
treatment, HSIL but no treatment). 
Patient involvement 
Patients and the wider public were involved from the outset through informal interviews in 
the clinic and through patient advocate representative bodies. The research questions and 
outcomes were developed based on the patients’ concerns and priorities. Patients were not 
involved in the interpretation of results or writing of the article. The results will be 
disseminated to the lay audience through the authors' involvement with charities, through 
public presentations and interviews. 
 
RESULTS 
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We identified 406 potentially eligible studies; 71 (5, 11-14, 27-92) fulfilled the inclusion 
criteria of this review. No unpublished studies were identified. We excluded studies without 
an untreated reference population (93-118), studies that included women treated during 
pregnancy (119, 120), studies assessing fertility and early pregnancy outcomes below 24 
weeks of gestation (121-126), studies assessing outcomes post-treatment in high-risk 
populations (127, 128) and studies assessing the impact of CIN on outcomes without 
information as to whether treatment was performed (129-131). More details of the 
literature search and the reasons for exclusion are presented in the PRISMA flowchart (132) 
(Figure 1). 
The detailed characteristics of the included studies and the outcomes examined are shown 
in Supplementary Table 2. The majority of the studies were retrospective with only five 
prospective reports (70, 76, 77, 79, 81). All were cohort studies, apart from one case-control 
study by Castanon 2014 (84). There were no randomised controlled studies. Fourteen 
studies examined the impact of CKC (12, 27-29, 31-33, 36, 59-61, 81, 86, 88), 10 of LC (41, 
45-48, 50, 51, 55, 75, 77), one of NETZ (12), 34 of LLETZ (12, 38-40, 43, 44, 49, 54-59, 61, 62, 
64-68, 72, 73, 75-77, 79-82, 85-87, 89, 90), eight of LA (34, 37, 38, 46, 48, 53, 55, 61), one of 
RD (61), two of CT (30, 59), 16 of Excision NOS (5, 11, 13, 14, 52, 63, 69-71, 74, 77, 78, 83, 84, 
89, 92), five of Ablation NOS (11, 13, 52, 69, 86), and three of Treatment NOS (35, 42, 91). 
There were five types of untreated comparison groups. Some used an external comparator 
(5, 11-14, 27, 28, 32, 34-44, 47, 48, 50-54, 56-60, 63-80, 82, 85, 86, 88, 91, 92), others 
compared to the pre-treatment pregnancies of the treated population (internal) (5, 14, 29-
31, 33, 44-46, 57, 72, 73, 83, 90), or used self-matching for women that delivered both 
before and after treatment (internal) (12, 14, 42, 47, 50, 63, 65), some compared to women 
that attended colposcopy with or without CIN and/or biopsy but no treatment (14, 55, 61, 
62, 66, 67, 76, 80, 81, 83, 87, 89, 90, 92), and some to women with high-grade disease but 
no treatment (12, 52, 69). All studies that used an external comparison group either 
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matched for known risk factors or performed a regression analysis to control for known 
confounders; four studies (42, 60, 64, 75) did not control for any confounders. 
The quality assessment for observational studies with the Newcastle-Ottawa score is 
presented in more details in Supplementary Table 3. The majority of the studies scored eight 
or ine points, ten (29, 34, 42, 44-46, 49, 60, 71, 75) scored seven and two (37, 64) scored 
six.  
Preterm birth 
The risk preterm birth was significantly increased after cervical treatment (Table 1; Figure 2). 
This was the case for prematurity overall at less than 37 weeks of gestation (60 studies, 
5244560 women, 10.7 v 5.4%, RR=1.78 [1.60 to 1.98]), for severe prematurity less than 
34/32 weeks of gestation (25 studies, 3795351 women, 3.5 v 1.4%, RR=2.40 [1.92 to 2.99]) 
and extreme prematurity less than 30/28 weeks of gestation (nine studies, 3912106 women, 
1.0 v 0.3%, RR=2.54 [1.77 to 3.63]). The magnitude of the effect of treatment was higher for 
more radical treatment techniques and for excision rather than ablation. More specifically, 
the risk of preterm birth at less than 37 weeks of gestation was higher for CKC (RR=2.70 
[2.14 to 3.40]), LC (RR=2.11 [1.26 to 3.54]), excision NOS (RR=2.02 [1.60 to 2.55]), LLETZ 
(RR=1.56 [1.36 to 1.79]), ablation NOS (RR=1.46 [1.27 to 1.66]). Similar trends were noted 
for severe and extreme prematurity. Treatment also increased the risk of preterm birth for 
women with multiple pregnancies for some but not all treatments but the results were 
inconsistent due to the small number of studies. The impact of treatment was not different 
for nulliparous and multiparous women (data not shown). The effect of multiple as opposed 
to single treatments on the risk of prematurity was substantially higher as compared to 
untreated women (repeat treatment: 11 studies, 1317284 women, 13.2 v 4.1%, RR=3.78 
[2.65 to 5.39]; single treatment: 17 studies, 1367023 women, 7.5 v 4.2%, RR=1.75 [1.49 to 
2.06]). The relative risk of preterm birth for two excisional treatments NOS was as high as 
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5.48 [2.68 to 11.24] and that of two loop excisions as high as 2.81 [2.33 to 3.39] as compared 
to no treatment. 
The analysis of the risk of preterm birth at less than 37 weeks of gestation according to the 
cone dimensions demonstrated that the risk increases progressively with increasing cone 
depth or volume (Table 2; Figure 3). The risk for treated versus untreated women was 
significantly increased for women with cone depth of less than 12/10 mm (eight studies, 
550929 women, 7.1 v 3.4%, RR=1.54 [1.09 to 2.18]) and the magnitude of effect increased 
with increasing cone depth (≥10/12mm: eight studies, 552711 women, 9.8 v 3.4%, RR=1.93 
[1.62 to 2.31]; ≥15/17mm: four studies, 544248 women, 10.1 v 3.4%, RR=2.77 [1.95 to 3.93]; 
≥20mm: three studies, 543750 women, 10.2 v 3.4%, RR=4.91 [2.06 to 11.68]). The trend was 
similar with increasing cone volume (<6cc: one study, 550 women, 8.1 v 3.6%, RR=2.25 [1.09 
to 4.66]; >6cc: one study, 284 women, 50.0 v 3.6%, RR=13.9 [5.09 to 37.98]). Further 
analyses of the individual cone depth cut-offs not grouped together revealed similar results 
(data not shown).  
The comparison of treated women for different cone depths revealed that deep excisions 
significantly increased the risk of preterm birth (<37 weeks) as opposed to less deep 
excisions and the magnitude of the effect increased in deeper cones (≥10/12mm v 
≤12/10mm: seven studies, 6359 women, 12.3 v 7.8%, RR=1.54 [1.31 to 1.80]; ≥15/17mm v ≤ 
17/15mm: four studies, 4275 women, 10.1 v 5.7%, RR=1.82 [1.47 to 2.26]; ≥20mm v ≤20mm: 
three studies, 3944 women, 10.2 v 5.6%, RR=2.79 [1.24 to 6.27])(Supplementary table 4; 
Figure 4). The findings were similar for the comparison of cone volumes (>3/4cc v <4/3cc: 
one study, 278 women, 15.0 v 7.3%, RR=2.04 [0.95 to 4.39]; >6cc v <6cc: one study, 278 
women, 50.0 v 8.1%, RR=6.18 [2.53 to 15.13]). 
The impact that the choice of comparison group may have on the magnitude of effect was 
assessed by a subgroup analysis that classified different studies according to the comparator 
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used (Table 3). The results suggested that treatment significantly increased the risk of 
preterm birth at less than 37 weeks of gestation irrespective of the comparison group used. 
The magnitude of effect was higher when an external comparison group was used (46 
studies, 5193761 women, 10.6 v 5.4%, RR=1.93 [1.71 to 2.17]), followed by internal 
comparators (self-matching: seven studies, 2916 women, 10.8 v 7.1%, RR=1.52 [1.17 to 
1.97]; pre-treatment pregnancies: 14 studies, 83528 women, 14.1 v 6.4%, RR=1.42 [1.01 to 
1.99]) and ultimately women with disease but no treatment (13 studies, 74958 women, 8.8 v 
6.0%, RR=1.27 [1.14 to 1.41]). When the pregnancies of the women with disease but no 
treatment and the pregnancies of the treated women before treatment were compared to 
the general population, the risk of preterm birth was significantly increased (17 studies, 
4359362 women, 5.9 v 5.6%, RR=1.24 [1.14 to 1.35]).  
The subgroup analysis of the risk of preterm birth (<37 weeks) according to cone depth and 
comparison group revealed similar direction of effect, although for cone depth of cone 
depth of less or equal to 12/10mm the difference became insignificant. The number of 
studies was however small for many comparisons [treated v untreated with CIN = cone 
depth ≤12/10mm: 4 studies, 43145 women, 7.0 v 5.0%, RR=1.11 [0.85 to 1.43]; ≥10/12mm: 4 
studies, 45275 women, 9.6 v 5.0%, RR=1.52 [1.37 to 1.68]; ≥15/17mm: 3 studies, 33934 
women, 9.6 v 4.3%, RR=2.30 [1.57 to 3.35]; ≥20mm: 2 studies, 32717 women, 9.3 v 4.2%, 
RR=4.32 [0.93 to 20.03])(Supplementary Table 5). Furthermore, the sensitivity analysis that 
excluded studies that scored below the median Newcastle-Ottawa score (median=8.3) did 
not change the results of the analysis; similarly the results did not change when we excluded 
studies with a score less or equal to 7 and 6 (data not shown). The subgroup analyses of 
studies based on the cohort selection or the comparability of the comparison groups 
showed similar direction and magnitude of effect (data not shown). The mono-variate meta-
regression analysis suggested that the type of treatment and comparator significantly 
affected the risk of PTB, although the type of treatment and Newcastle-Ottawa score did 
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not. These factors remained significant when these were assessed in a multivariate 
regression analysis. When we performed further meta-regression restricting only to 
excisional treatments and using as a comparator women with colposcopy/biopsy, we found 
that all treatment were associated with an increased risk of PTB (LLETZ, RR=1.34 [1.10 to 
1.64]; CKC, RR=2.3 [1.39, 3.85]; LC, RR=1.6 [0.91 to 2.87]; NETZ, RR=4.26 [1.96 to 9.33].  
 
Other Maternal outcomes 
Maternal outcomes other than preterm birth were assessed in several studies 
(Supplementary Table 6) and many of these were found to be increased after cervical 
treatment. This increase was more frequent for excisional as opposed to ablative techniques 
and with increasing treatment radicality, although the number of studies assessing each 
individual treatment method was frequently small. 
Cervical treatment increased the risk of spontaneous overall, severe and extreme preterm 
birth (<37 weeks: 14 studies, 1024731 women, 7.0 v 3.7%, RR=1.76 [1.47 to 2.11]; <34/32 
weeks: seven studies, 655675 women, 1.8 v 0.6%, R=2.63 [1.91 to 3.62]; <28 weeks: two 
studies, 626670 women, 0.6 v 0.2%, RR=3.18 [1.64 to 6.16]) and the admissions for 
threatened preterm birth (five studies, 903 women, 9.1 v 3.2%, RR=2.44 [1.37 to 4.33]). The 
risk (<37 weeks) was higher for CKC (RR=3.53 [2.05 to 6.05]) followed by excision NOS 
(RR=1.70 [1.17 to 2.46]), LLETZ (RR=1.60 [1.22 to 2.08]) and ablation NOS (RR=1.42 [1.20 to 
1.70]). NETZ and LA were only assessed in one study, respectively. There was substantial 
heterogeneity for the comparisons assessing outcomes at less than 32/34 and 28 weeks of 
gestation (P-value<0.05). 
The risk of pPROM (<37 weeks: 21 studies, 477011 women, 6.1 v 3.4%, RR=2.36 [1.76 to 
3.17]) and chorioamnionitis (four studies, 29198 women, 3.5 v 1.1%, RR=3.43 [1.36 to 8.64]) 
was also increased after treatment. The risk of pPROM was higher for CKC (RR=4.11 [2.05 to 
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8.25]) followed by LLETZ (RR=2.15 [1.48 to 3.12]). NETZ was only assessed in one study and 
LA did not significantly affect the risk but was only assessed in two studies. 
The mode of delivery (caesarean section or instrumental delivery), the length of labour 
(precipitous or prolonged), the use of analgesia (epidural, pethidine or other), the rate of 
induction of labour (with or without oxytocin), cervical stenosis or haemorrhage (antenatal 
or postpartum) was not affected by treatment. As expected, the rate of cervical cerclage 
insertion was higher for treated as opposed to non-treated women (eight studies, 141300 
women, 4.0 v 0.7%, RR=14.29 [2.85 to 71.65] and more so for CKC (RR=31.42 [2.32 to 
426.2]), LLETZ (RR=11.0 [0.64 to 190]) or excisional treatment not otherwise specified 
(RR=42.45 [28.99 to 62.16]). 
Neonatal outcomes 
More than 30 studies assessed one or more neonatal outcomes (Supplementary Table 7). 
Cervical treatment (excisional or ablative) was associated with a significant increase in 
adverse neonatal outcomes as opposed to women having no treatment (comparison group 
not specified). The association with adverse neonatal events was stronger and more 
frequent for excisional as opposed to ablative techniques and with increasing treatment 
radicality, although the number of studies for each individual treatment technique was often 
limited.  
More specifically, cervical treatment overall increased the risk of low birth weight (less than 
2500g: 30 studies, 1348206 women, 7.9 v 3.7%, RR=1.81 [1.58 to 2.07); less than 1500g: five 
studies, 76836 women, 2.0 v 0.5%, RR=3.00 [1.54 to 5.85]), neonatal intensive unit 
admission (eight studies, 2533 women, 12.6 v 9.1%, RR=1.44 [1.14 to 1.82]) and perinatal 
mortality (23 studies, 1659433 women, 0.9 v 0.7%, RR=1.51 [1.13 to 2.03]). There was 
significant inter-study heterogeneity for perinatal mortality (P-value=0.04, I
2
=36%). 
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The rate of neonates born with birth weight of less than 2500g was significantly higher for 
women treated with CKC (five studies, 1348206, RR=2.51 [1.78 to 3.53]), LLETZ (12 studies, 
3357, RR=2.11 [1.51 to 2.94]), excisional (ten studies, 823648, RR=2.01 [1.62 to 2.49]) or 
ablative (four studies, 483402, RR=1.36 [1.19 to 1.55]) treatment not otherwise specified but 
not so for laser ablation (RR=1.07 [0.59 to 1.92]), although only four studies with a total of 
1104 participants assessed that comparison. The rate of NICU admission was only assessed 
for excisional techniques and was significantly increased after LLETZ (five studies, 1994 
women, RR=1.42 [1.01 to 1.99]). Perinatal mortality was significantly increased overall and 
for excisional technique not otherwise specified (five studies, 820028, RR=1.85 [1.02 to 
3.36]) but not for the individual techniques possibly due to the limited number of studies 
and the low prevalence of the outcome. Subgroup analysis according to the different 
comparison groups or cone depths was not possible due to the limited number of studies 




The knowledge that local treatment for cervical precancer, particularly excisional, increases 
the risk of preterm birth has led to major changes in clinical practice. With a rapidly evolving 
evidence base and inconsistencies in the published literature (13, 14, 16, 17, 65, 112), a high 
quality synthesis of the evidence should be available for effective patient counseling at 
colposcopy and antenatal clinics.  
This meta-analysis documents that any local cervical treatment for cervical pre-invasive or 
early invasive disease increases the risk of preterm birth and adverse sequelae in a 
subsequent pregnancy, although the impact of small excisions as opposed to just having the 
disease remains uncertain and is likely to be small. Cervical treatment was found to be 
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associated with an increased risk of overall, severe and extreme prematurity, spontaneous 
preterm birth, threatened preterm labour, pPROM, chorioamnionitis, low birth weight, 
neonatal admission and perinatal death. The rate of cervical cerclage was unsurprisingly 
substantially increased in treated women as opposed to untreated controls. Treatment 
equally affected outcomes for nulliparous as well as parous, singleton and multiple 
pregnancies. The mode of delivery, length of labour, the induction rate, the use of analgesia, 
the rate of stenosis and haemorrhage were not significantly affected. 
The magnitude of the effect of treatment was higher for more radical techniques (ie. CKC 
followed by LLETZ and LA) and for excision rather than ablation. Multiple conisations 
increased four-fold the risk of preterm birth as compared to untreated controls overall. 
Subgroup analyses clearly demonstrated that the risk of preterm birth directly correlates to 
the cone dimensions (depth/volume) and progressively increases with increasing cone depth 
(‘dose-effect’). Although the risk was increased even for excisions measuring less than 10mm 
in depth, this was almost two-fold higher for excisions of more than 10mm, three-fold higher 
for more than 15/17mm and almost five-fold higher for excisions exceeding 20mm in depth. 
It has been previously suggested that the impact of treatment on the risk of preterm birth 
may not be a consequence of treatment but rather a product of other confounders present 
in women with cervical disease (7, 13, 14). Our subgroup analyses that stratified the risk to 
the comparator used, clearly documents that although the risk of preterm birth is 
significantly increased after treatment irrespective of the comparison group used, the choice 
of comparator may over-inflate or under-estimate the effect from treatment. The magnitude 
of effect was higher when external controls were used, followed by internal control, 
followed by women that had disease but were not treated. The analyses in women with HSIL 
but no treatment only included three studies and 3764 participants; we were unable to draw 
any firm conclusions from this comparison. When we assessed the risk of PTB according to 
both the cone depth and comparator, we noted overall the same direction of effect. 
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Although the difference in the risk of preterm birth for small excisions (≤10/12mm) as 
opposed to just having CIN but no treatment became insignificant, the number of studies 
assessing that comparison was however small and firm conclusions cannot be drawn. 
Our results also confirm that although women with CIN have a higher baseline risk of 
prematurity as compared to the general population, cervical treatment and particularly deep 
cones further increase that risk.  
 
Strengths and limitations 
This is the first systematic review to demonstrate that any local cervical treatment technique 
(excisional or destructive) is associated with an increased risk of preterm birth and adverse 
obstetric sequelae and to document that the risk directly correlates to the cone depth (and 
volume), the treatment technique (excision more than ablation) and radicality. This meta-
analysis included a large number of studies (71 cohorts) with sufficient sample size and 
power to explore several comparisons of treatment techniques and cone depths. 
Furthermore, we were able to perform subgroup analyses according to the comparator used 
and quantify the risk in different clinical groups.  
However, the results should be interpreted with caution. Due to the pre-malignant nature of 
the disease, no randomised studies could be identified. All the included studies were 
cohorts, in the vast majority retrospective. Such reports are at known risk of recall bias and 
inadequate adjustment for known and unknown confounders, while some of the outcomes 
of interest were difficult to objectively measure. Many of the studies relied on data collected 
from structured interviews and mailed questionnaires and in some of these the response 
rate was small, increasing also the risk of incomplete outcome data (attrition) and 
misclassification bias. The studies often had different designs and used comparisons 
between and amongst women and mixed matching. Although the overall number of studies 
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was large, for some outcomes and comparisons the numbers of studies was small and the 
analyses did not have sufficient sample sizes to support definite conclusions.  
Although the inter-study heterogeneity was not significant for the majority of the analyses, 
some subgroup analyses did demonstrate variation in the outcomes across studies. This was 
often in analyses that included small number of studies and participants. Meta-regression 
was possible for some but not all possible confounders. For many moderators, the data was 
reported only in a proportion of the included studies. When these studies were not deemed 
representative of the whole population of studies, we did not perform meta-regression as 
this would introduce bias. Sensitivity and subgroups analyses based on the studies’ quality 
did not change the effect of the meta-analysis.  
There were further limitations in the interpretation of the data. The cut-off used for the 
definitions of severe and extreme prematurity and for different cone depths varied slightly 
across studies; these were merged in broader groups for the analysis. Individual patient 
meta-analysis data is required to more accurately describe the stratified risk of preterm birth 
for individual cone depths. The data on the cone dimensions relied on retrospective 
documentation data recorded in histopathology reports of formalin-fixed samples with 
obvious limitations. The formulas used for the volume calculation also varied across studies. 
Future research should aim to correlate outcomes with prospective precise cone depth and 
cervical measurements. 
Both the included and excluded studies demonstrated a wide range of inclusion / exclusion 
criteria and outcome measures limiting statistical pooling of all the primary studies. There 
should be agreement amongst colposcopists and obstetricians on core research clinical 
outcome measures in line with the CROWN initiative of the premier reproductive health 
journals(133). This would improve the applicability of findings of primary and secondary 
research internationally.  
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Interpretation in light of other evidence 
The knowledge that local treatment for cervical precancer, particularly excisional, increases 
the risk of preterm birth has led to major changes in clinical practice. With an increasing 
evidence base suggesting that this risk is higher for more radical techniques, there has been 
a tendency to use less aggressive treatments (5). Although it was previously thought that the 
various techniques had comparable efficacy (134), evidence from a population-based study  
raised concerns that less radical treatment may increase the risk of post-treatment invasion 
(135, 136). Although the decreased number of hysterectomies may explain this increase, the 
move to less radical local conservative treatments is another plausible explanation. 
Additionally, since the first documentation of the reproductive risk associated with 
treatment almost a decade ago (1), subsequent observational studies and even meta-
analyses reached contradictory conclusions (2-4, 15-18) and initiated debates within the 
scientific community. With some authors raising concerns that the progressive reduction in 
the radicality of treatment has led to increased risk of future of invasion (135, 136), and 
others advocating the move to less radical techniques like laser ablation for the prevention 
treatment-associated future perinatal morbidity and mortality (137), high quality synthesis 
of the evidence had become an urgent unmet need. Some of the previous small meta-
analyses suffered methodological flaws and attempted analysis of individual treatment 
techniques or subgroups minimising the validity of their findings in context with the rest of 
the literature(15-17). All the published meta-analyses failed to analyse the data according to 
major confounders and stratifiers of risk, the comparison group and the depth of the 
excision. Although Bruinsma et al.(4) first approached the comparison group as a possible 
confounder, data on the depth and dimensions of the treatment was not available. 
Preterm birth is a major cause of neonatal death and disability and represents an enormous 
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cost to the health services and the society. While pregnant, these women make up a large 
proportion of preterm clinics referrals. These referrals have increased from almost none in 
1999, to more than 40% in 2012 (138). Ultrasound-directed surveillance is labour intensive, 
costly, and may be associated with maternal anxiety, more so because 85% of women post-
excision are effectively low risk and will deliver at term (1, 4).  
With rapidly accumulating evidence correlating cervical treatment to adverse reproductive 
morbidity, quantification of the comparative obstetric morbidity for different treatment 
techniques and cone depths was required to assist clinicians decision-making and 
counseling. The results of this meta-analysis will allow clinicians, patients and policy makers 
to balance the absolute increase in reproductive morbidity with increasing treatment 
radicality. Patients should be informed that treatment increases the risk of preterm birth as 
opposed to having CIN only, but the absolute increase in risk in small type 1 excisions is likely 
to be low, if any.  
Furthermore, the quantified individual risk stratified by treatment and cone depth could 
allow obstetricians the selection of those considered to be at high risk of preterm birth that 
would benefit from intensive surveillance antenatally and minimize the unnecessary 
interventions for those at low risk. The antenatal management of women after treatment 
has been inconsistent and largely unit- or clinician-dependent
29
. The risks and benefits 
associated with various interventions in pregnant women with a history of cervical 
treatment have not been fully assessed in properly designed studies (139). Future research 
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Women with CIN have a higher baseline risk of preterm birth as compared to women from 
the general population. Local cervical treatment for pre-invasive or early invasive disease 
further increases the risk more so for excisional but also for ablative techniques. The risk of 
preterm birth increases with increasing cone depth (and volume) and techniques that 
remove or destroy larger parts of the cervix. The increase in risk for small excisions as 
opposed to having CIN is likely to be small, if any. 
When deciding to treat women of reproductive age, every effort should be made to perform 
a local treatment that will optimise the chances of a healthy pregnancy without 
compromising the completeness of the local treatment. Quality assurance in treatment of 
disease should include audit of dimensions of excisional specimens and persistent disease 
rates to ensure that treatment depth is kept to acceptable parameters (ie. at least 8mm to 
involved crypts) and that oncological outcomes are not compromised. 
Future research should investigate if women who have pre-invasive cervical disease are both 
susceptible to the disease and preterm birth, or whether HPV induced disease alone is the 
principal factor in increasing premature delivery. It is likely that a combination of 
immunological and other factors play a role. The uptake of prophylactic vaccination has 
been mixed in the developed world and minimal in low-income countries.  The impact of 
cervical treatment is still going to be relevant for many decades and therefore robust clinical 
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What this study adds 
What is already known on this subject 
• Local cervical treatment has been correlated to an increased risk of preterm birth, 
perinatal morbidity and mortality in a subsequent pregnancy, which may be associated with 
depth of excision. 
• Discrepancies exist regarding the impact of treatment on the risk of subsequent PTB, and 
whether CIN acts as a confounder, which may be due to the heterogeneity in comparison 
groups used in previous studies or on how different excision depths and/or treatment 
techniques have been analysed. 
What this study adds 
• Increased risk of adverse obstetric outcomes correlates directly to the treatment 
technique (excision more than ablation) and radicality, determined by the depth and 
dimensions of the cone. 
• Although the risk of preterm birth is higher after local treatment for CIN irrespective of 
the cone depth, the risk increases with increasing cone depth. The increase in risk in small 
excisions when compared to just having CIN is likely to be small or absent, but more data is 
required.  
• Choice of comparison group may over-inflate or under-estimate the effect from treatment, 
due to the background increased risk of PTB in women with CIN. However, the increased risk 
of PTB remains significantly increased after treatment, in spite of the chosen comparator 
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Figure legends 
Figure 1: PRISMA flowchart 
Figure 2: Meta-analysis on preterm birth (<37weeks) in treated versus untreated women  
Figure 3: Meta-analysis on preterm birth (<37 weeks) in treated versus untreated women 
according to the cone depth a) ≤10/12mm; b) ≥10/12mm; c) ≥15/17mm d) ≥20mm 
Figure 4: Meta-analysis on preterm birth (<37 weeks) in women treated with a cone depth a) 
≥10/12mm versus ≤10/12mm; b) ≥15/17mm versus ≤17/15mm; c) ≥20mm versus ≤20mm
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Table 1: Preterm birth for treated versus untreated women and also according to number of fetuses and treatments* 
 
Preterm birth outcome Studies Total        N Treated                              Untreated                             Effect Estimate                                                                                   Heterogeneity
PTB       
PTB (<37w)       
All Treatment types 60 5244560 6506/60619 (10.7) 281575/5183941 (5.4) 1.78 [1.60 to 1.98] <0.001 (88) 
CKC 12 39102 126/844 (14.9) 2321/38258 (6.1) 2.70 [2.14 to 3.40] 0.62 (0) 
LC 9 1464 96/672 (14.3) 58/792 (7.3) 2.11 [1.24 to 3.57] 0.02 (56) 
NETZ 1 7399 17/71 (23.9) 301/7328 (4.1) 5.83 [3.80 to 8.95] N/E (N/E) 
LLETZ 26 1445341 1724/21318 (8.1) 66607/1424023 (4.7) 1.56 [1.36 to 1.79] <0.001 (69) 
LA 7 4710 168/1867 (9.0) 242/2843(8.5) 1.04 [0.86 to 1.26] 0.48 (0) 
CT 2 238 4/151 (2.6) 2/87 (2.3) 1.02 [0.22 to 4.77] 0.67 (0) 
RD 1 2150 109/760 (14.3) 123/1390 (8.8) 1.62 [1.27 to 2.06] N/E (N/E) 
Excisional Treatment NOS 15 3107438 3788/28104 (13.4) 183133/3079334 (5.9) 2.02 [1.60 to 2.55] <0.001 (95) 
Ablative Treatment NOS 5 595272 430/6482 (6.6) 26804/588790 (4.6) 1.46 [1.27 to 1.66] 0.22 (30) 
Treatment NOS 3 41401 44/350 (12.6) 1979/41051 (4.8) 2.20 [1.28 to 3.78] 0.07 (62) 
PTB (<34/32w)**       
All Treatment types 25 3795351 1375/39647 (3.5) 53835/3755704 (1.4) 2.40 [1.92 to 2.99] <0.001 (82) 
CKC 5 36979 15/283 (5.3) 920/36696 (2.5) 3.07 [1.72 to 5.49] 0.65 (0) 
NETZ 1 7399 5/71 (7.0) 49/7328 (0.7) 10.53 [4.33 to 25.65) N/E (N/E) 
LLETZ 11 791554 237/11569 (2.0) 9504/779985 (1.2) 2.13 [1.66 to 2.75] 0.08 (40) 
CT 1 58 1/36 (2.8) 0/22 (0.0) 1.86 [0.08 to 43.87] N/E (N/E) 
Excisional Treatment NOS 10 2832112 1000/22562 (4.4) 42598/2809550 (1.5) 3.05 [1.95 to 4.78] <0.001 (91) 
Ablative Treatment NOS 2 120762 26/2549 (1.0) 686/118213 (0.6) 1.59 [1.08 to 2.35] 0.92 (0) 
Treatment NOS 2 6487 91/2577 (3.5) 78/3910 (2.0) 1.65 [1.13 to 2.42] 0.25 (24) 
PTB (<30/28w)**       
All Treatment types 9 3912106 403/39154 (1.0) 12887/3872952 (0.3) 2.54 [1.77 to 3.63] <0.001 (81) 
CKC 2 7118 2/150 (1.3) 19/6968 (0.3) 4.52 [0.83 to 24.54] 0.74 (0) 
NETZ 1 7399 3/71 (4.2) 21/7328 (0.3) 14.74 [4.50 to 48.32] N/E (N/E) 
LLETZ 3 502778 59/8899 (0.7) 1224/493879 (0.2) 2.57 [1.97 to 3.35] 0.9 (0) 
Excisional Treatment NOS 4 2821185 287/21984 (1.3) 9854/2799201 (0.4) 2.90 [1.52 to 5.52] <0.001 (88) 
Ablative Treatment NOS 3 568217 23/6125 (0.4) 1739/562092 (0.3) 1.38 [0.81 to 2.36] 0.21 (35) 
Treatment NOS 1 5409 29/1925 30/3484 1.75 [1.05 to 2.91] N/E (N/E) 
Singleton/Multiple pregnancies       
PTB (<37w) & Singleton pregnancies       
All Treatment types 32 2189620 2907/33330 (8.7) 110981/2156290 (5.1) 1.76 [1.57 to 1.98]  <0.001 (78) 
CKC 6 37759 83/495 (16.8) 2286/37264 (6.1) 2.89 [2.22 to 3.77] 0.62 (0) 
LC 4 545 52/249 (20.9) 24/296 (8.1) 2.54 [1.24 to 5.2] 0.08 (55) 
NETZ 1 7399 17/71 (23.9) 301/7328 (4.1) 5.83 [3.80 to 8.95] N/E (N/E) 
LLETZ 18 1444175 1660/20812 (8.0) 66533/1423363 (4.7) 1.61 [1.39 to 1.87] <0.001 (76) 
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LA 3 3420 129/1325 (9.7) 188/2095 (9.0) 1.10 [0.75 to 1.62] 0.18 (42) 
CT 1 58 1/36 (2.8) 0/22 (0.0) 1.86 [0.08 to 43.87] N/E (N/E) 
RD 1 2150 109/760 (14.3) 123/1390 (8.8) 1.62 [1.27 to 2.06] N/E (N/E) 
Excisional Treatment NOS 6 542622 713/7133 (10.0) 35877/535489 (6.7) 1.43 [1.15 to 1.77] 0.05 (56) 
Ablative Treatment NOS 2 110091 99/2099 (4.7) 3670/107992 (3.4) 1.14 [0.56 to 2.32] 0.2 (40) 
Treatment NOS 3 41401 44/350 (12.6) 1979/41051 (4.8) 2.20 [1.28 to 3.78]  0.07 (62) 
PTB (<37w) & Multiple pregnancies       
All Treatment types 6 10825 138/299 (46.2) 3585/10526 (34.1) 1.13 [0.95 to 1.34] 0.25 (23) 
CKC 2 84 5/13 (38.5) 37/71 (52.1) 0.95 [0.49 to 1.83] 1 (0) 
LLETZ 4 10227 98/219 (44.7) 3308/10008 (33.1) 1.26 [1.08 to 1.46] 0.44 (0) 
Excisional Treatment NOS 1 4 3/3 (100.0) 0/1 (0.0) 3.5 [0.31 to 39.71] N/E (N/E) 
Ablative Treatment NOS 1 510 32/64 (50.0) 240/446 (53.8) 0.93 [0.72 to 1.20] N/E (N/E) 
PTB (<34/32w) & Multiple pregnancies       
All Treatment types 3 10789 38/286 (13.3) 715/10503 (6.8) 1.68 [0.95 to 2.98] 0.08 (52) 
CKC 1 80 4/10 (40.0) 8/70 (11.4) 3.5 [1.29 to 9.52] N/E (N/E) 
LLETZ 3 10199 28/212 (13.2) 658/9987 (6.6) 1.76 [0.88 to 3.5] 0.21 (36) 
Ablative Treatment NOS 1 510 6/64 (9.4) 49/446 (11.0) 0.85 [0.38 to 1.91] N/E (N/E) 
PTB (<28w) & Multiple pregnancies       
All Treatment types 2 10744 12/276 (4.3) 237/10468 (2.3) 2.43 [1.40 to 4.22] 0.88 (0) 
CKC 1 80 0/10 (0.0) 1/70 (1.4) 2.15 [0.09 to 49.56] N/E (N/E) 
LLETZ 2 10154 10/202 (5.0) 230/9952 (2.3) 2.45 [1.34 to 4.47] 0.42 (0) 
Ablative Treatment NOS 1 510 2/64 (3.1) 6/446 (1.3) 2.32 [0.48 to 11.26] N/E (N/E) 
Number of treatments       
PTB (<37w) & Single treatment       
All Treatment types 17 1367023 1519/20302 (7.5) 56185/1346721 (4.2) 1.75 [1.49 to 2.06] <0.001 (79) 
CKC 3 36783 38/179 (21.2) 2250/36604 (6.1) 2.89 [2.08 to 4.03] 0.42 (0) 
LC 2 657 34/335 (10.1) 29/322 (9.0) 1.06 [0.54 to 2.09] 0.17 (48) 
NETZ 1 7399 17/71 (23.9) 301/7328 (4.1) 5.83 [3.80 to 8.95] N/E (N/E) 
LLETZ 9 1277874 1139/16755 (6.8) 51075/1261119 (4.0) 1.74 [1.45 to 2.10] <0.001 (75) 
LA 4 1421 58/624 (9.3) 68/797 (8.5) 1.07 [0.66 to 1.74] 0.17 (40) 
Excisional Treatment NOS 3 32106 197/1816 (10.8) 1840/30290 (6.1) 1.88 [1.20 to 2.93] 0.1 (57) 
Ablative Treatment NOS 1 10783 36/522 (6.9) 622/10261 (6.1) 1.14 [0.82 to 1.57] N/E (N/E) 
PTB (<37w) & Repeat treatment       
All Treatment types 11 1317284 191/1442 (13.2) 54142/1315842 (4.1) 3.78 [2.65 to 5.39] <0.001 (75) 
CKC/LA 1 99 2/2 (100.0) 6/97 (6.2) 12.56 [5.11 to 30.87] N/E (N/E) 
LC/LC 1 270 6/20 (30.0) 20/250 (8.0) 3.75 [1.70 to 8.27] N/E (N/E) 
LLETZ/ LLETZ 4 1202174 139/1195 (11.6) 48586/1200979 (4.0) 2.81 [2.33 to 3.39] 0.35 (9) 
LLETZ/ Treatment NOS 1 298 9/41 (22.0) 6/257 (2.3) 9.40[3.53 to 25.03] N/E (N/E) 
Excisional NOS/ Excisional Treatment NOS 3 73651 17/57 (29.8) 3034/73594 (4.1) 5.48 [2.68 to 11.24] 0.16 (45) 
Treatment NOS/ Treatment NOS 2 40792 18/127 (14.2) 2490/40665 (6.1) 1.71 [1.10 to 2.67] 0.85 (0) 
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*If a study had more than one comparison groups, we used external groups (external general, external untreated women that had colposcopy+/-CIN+/-
biopsy, women with HSIL but no treatment) in preference to internal comparators (self-matching or pre-treatment pregnancies).  
** In cases of heterogeneity in the cut-offs used for prematurity classification, these were grouped together when possible (ie. 34/32 or 30/28 weeks to 
include both cut-offs). 
CIN: cervical intraepithelial neoplasia; CKC: cold knife conisation; CT: cryotherapy; HSIL: high-grade squamous intraepithelial lesion; LA: laser ablation; LC: 
laser conisation; LLETZ: large loop excision of the transformation zone; N/E: not eligible; NETZ: needle excision of the transformation zone; NOS: not 



























































































Confidential: For Review Only
 31
Table 2: Preterm birth (<37 weeks) for treated women versus untreated women according to the cone dimensions (depth/volume) 
 
Treated Group Studies Total        
N 
Treated                              
n/N (%) 
Untreated                             
n/N (%) 
Effect Estimate                                                                                   






Cone Depth       
Cone Depth ≤ 12/10mm**       
All Treatment types 8 550929 293/4105 (7.1) 18720/546824 (3.4) 1.54 [1.09 to 2.18] 0.004 (67) 
LC 1 105 1/41 (2.4) 3/64 (4.7) 0.52 [0.06 to 4.83] N/E (N/E) 
LLETZ 3 544907 98/1600 (6.1) 18448/543307 (3.4) 2.01 [1.28 to 3.15] 0.13 (51) 
Excisional Treatment NOS 4 5917 194/2464 (7.9) 269/3453 (7.8) 1.20 [0.78 to 1.85] 0.15 (44) 
Cone Depth ≥ 10/12mm       
All Treatment types 8 552711 571/5845 (9.8) 18723/546866 (3.4) 1.93 [1.62 to 2.31] 0.13 (37) 
LC 1 87 5/23 (21.7) 3/64 (4.7) 4.64 [1.20 to 17.88] N/E (N/E) 
LLETZ 3 546134 193/2827 (6.8) 18448/543307 (3.4) 2.29 [1.57 to 3.34] 0.2 (37.23) 
Excisional Treatment NOS 4 6490 373/2995 (12.5) 272/3495 (7.8) 1.68 [1.41 to 1.99] 0.37 (5.32) 
Cone Depth ≤ 15/17mm       
All Treatment types 4 545939 149/2614 (5.7) 18493/543325 (3.4) 1.36 [1.15 to 1.61] 0.61 (0) 
LC  1 164 0/14 (0.0) 7/150 (4.7) 0.67 [0.04 to 11.18] N/E (N/E) 
LLETZ 2 545119 117/2370 (4.9) 18434/542749 (3.4) 1.42 [1.18 to 1.70] 0.41 (0) 
Excisional Treatment NOS 1 656 32/230 (13.9) 52/426 (12.2) 1.14 [0.76 to 1.72] N/E (N/E) 
Cone Depth ≥ 15/17mm       
All Treatment types  4 544986 167/1661 (10.1) 18493/543325 (3.4) 2.77 [1.95 to 3.93] 0.1 (53) 
LC 1 211 14/61 (23.0) 7/150 (4.7) 4.92 [2.09 to 11.59] N/E (N/E) 
LLETZ 2 544248 128/1499 (8.5) 18434/542749 (3.4) 3.16 [1.54 to 6.48] 0.08 (67) 
Excisional Treatment NOS 1 527 25/101 (24.8) 52/426 (12.2) 2.03 [1.33 to 3.10] N/E (N/E) 
Cone Depth ≤ 20mm       
All Treatment types 3 545992 174/3093 (5.6) 18441/542899 (3.4) 1.60 [1.38 to 1.87] 0.62 (0) 
LC 1 183 2/33 (6.1) 7/150 (4.7) 1.30 [0.28 to 5.97] N/E (N/E) 
LLETZ 2 545809 172/3060 (5.6) 18434/542749 (3.4) 1.61 [1.38 to 1.87] 0.35 (0) 
Cone Depth ≥ 20mm       
All Treatment types 3 543750 87/851 (10.2) 18441/542899 (3.4) 4.91 [2.06 to 11.68] 0.01 (77) 
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LC 1 192 12/42 (28.6) 7/150 (4.7) 6.12 [2.57 to 14.57] N/E (N/E) 
LLETZ 2 543558 75/809 (9.3) 18434/542749 (3.4) 4.72 [1.25 to 17.80] 0.01 (83) 
Cone Depth = 10/13-15/16mm       
All Treatment types 3 544534 75/1359 (5.5) 18486/543175 (3.4) 1.32 [1.04 to 1.66] 0.82 (0) 
LLETZ 2 543994 57/1245 (4.6) 18434/542749 (3.4) 1.32 [1.02 to 1.72] 0.53 (0) 
Excisional Treatment NOS 1 540 18/114 (15.8) 52/426 (12.2) 1.29 [0.79 to 2.12] N/E (N/E) 
Cone Depth = 15/16-19/20mm       
All Treatment types  3 543608 55/709 (7.8) 18441/542899 (3.4) 2.24 [1.73 to 2.91] 0.42 (0) 
LC 1 169 2/19 (10.5) 7/150 (4.7) 2.26 [0.50 to 10.08] N/E (N/E) 
LLETZ 2 543439 53/690 (7.7) 18434/542749 (3.4) 2.53 [1.42 to 4.51] 0.19 (43) 
Cone Volume       
Cone Volume < 3cc       
All Treatment types 
(Volume<3cc) 
1 496 16/218 (7.3) 10/278 (3.6) 2.04 [0.94 to 4.41] N/E (N/E) 
LLETZ 1 496 16/218 (7.3) 10/278 (3.6) 2.04 [0.94 to 4.41] N/E (N/E) 
Cone Volume > 3cc       
All Treatment types 
(Volume>3cc) 
1 338 9/60 (15.0) 10/278 (3.6) 4.17 [1.77 to 9.82] N/E (N/E) 
LLETZ 1 338 9/60 (15.0) 10/278 (3.6) 4.17 [1.77 to 9.82] N/E (N/E) 
Cone Volume < 6cc       
All Treatment types  1 550 22/272 (8.1) 10/278 (3.6) 2.25 [1.09 to 4.66] N/E (N/E) 
LLETZ 1 550 22/272 (8.1) 10/278 (3.6) 2.25 [1.09 to 4.66] N/E (N/E) 
Cone Volume > 6cc       
All Treatment types 1 284 3/6 (50.0) 10/278 (3.6) 13.9 [5.09 to 37.98) N/E (N/E) 
LLETZ 1 284 3/6 (50.0) 10/278 (3.6) 13.9 [5.09 to 37.98] N/E (N/E) 
Cone Volume = 3-6cc       
All Treatment types 1 332 6/54 (11.1) 10/278 (3.6) 3.09 [1.17 to 8.14] N/E (N/E) 
LLETZ 1 332 6/54 (11.1) 10/278 (3.6) 3.09 [1.17 to 8.14] N/E (N/E) 
*If a study had more than one comparison groups, we used external groups (external general, external untreated women that had colposcopy+/-CIN+/-
biopsy, women with HSIL but no treatment) in preference to internal comparators (self-matching or pre-treatment pregnancies).  
** In cases of heterogeneity in the cut-offs used for cone depth classification, these were grouped together when possible: ie. 10/12mm in depth to include 
studies using either cut-off, ≥ or ≤ 12/10mm as some studies include depths equal to the cut-off and others did not). 
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CIN: cervical intraepithelial neoplasia; CKC: cold knife conisation; CT: cryotherapy; HSIL: high-grade squamous intraepithelial lesion; LA: laser ablation; LC: 
laser conisation; LLETZ: large loop excision of the transformation zone; N/E: not eligible; NETZ: needle excision of the transformation zone; NOS: not 
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Table 3: Preterm birth (<37 weeks) for treated and untreated women according to the comparison group. 
Comparison Group 1 Comparison Group 2 Studies Total        
N 
Treated                              
n/N (%) 
Untreated                             
n/N (%) 
Effect Estimate                                                                   
RR (95% CI) 
 
Heterogeneity
- p value (I
2
%) 
All Treatment types Untreated External  46 5193761 5888/55799 (10.6) 278963/5137962 (5.4) 1.93 [1.71 to 2.17] <0.001 (90) 
CKC  7 37370 62/390 (15.9) 2263/36980 (6.1) 3.28 [2.44 to 4.42] 0.99 (0) 
LC  6 1126 68/480 (14.2) 46/646 (7.1) 2.39 [1.24 to 4.61] 0.02 (63) 
NETZ  1 7361 17/71 (23.9) 300/7290 (4.1) 5.82 [3.79 to 8.94] N/E (N/E) 
LLETZ  20 1415006 1513/19934 (7.6) 65080/1395072 (4.7) 1.69 [1.46 to 1.97] <0.001 (68) 
LA  4 1258 37/510 (7.3) 50/748 (6.7) 1.27 [0.67 to 2.4] 0.19 (38) 
CT  1 58 1/36 (2.8) 0/22 (0.0) 1.86 [0.08 to 43.87] N/E (N/E) 
Excision NOS  12 3101232 3716/27546 (13.5) 182711/3073686 (5.9) 2.05 [1.61 to 2.60] <0.001 (96) 
Ablation NOS  5 588949 430/6482 (6.6) 26534/582467 (4.6) 1.45 [1.26 to 1.67] 0.19 (35) 
Treatment NOS  3 41401 44/350 (12.6) 1979/41051 (4.8) 2.20 [1.28 to 3.78] 0.07 (62) 
All Treatment types Internal (pre-Tx pregnancies) 14 83528 3117/22121 (14.1) 3949/61407 (6.4) 1.42 [1.01 to 1.99] <0.001 (89) 
CKC  3 1430 39/347 (11.2) 38/1083 (3.5) 1.79 [0.81 to 3.95] 0.15 (47) 
LC  2 161 8/87 (9.2) 3/74 (4.1) 1.65 [0.11 to 23.58] 0.06 (7) 
LLETZ  5 3331 192/1524 (12.6) 178/1807 (9.9) 1.21 [0.73 to 2.01] 0.002 (77) 
LA  1 226 16/129 (12.4) 10/97 (10.3) 1.20 [0.57 to 2.53] N/E (N/E) 
CT  1 180 3/115 (2.6) 2/65 (3.1) 0.85 [0.15 to 4.94] N/E (N/E) 
Excision NOS  3 78200 2859/19919 (14.3) 3718/58281 (6.4) 1.65 [0.88 to 3.08] <0.001 (96) 
All Treatment types Internal (self-matching) 7 2916 157/1458 (10.8) 103/1458 (7.1) 1.52 [1.17 to 1.97] 0.36 (9) 
LC  2 354 12/177 (6.8) 9/177 (5.1) 1.30 [0.56 to 3.06] 0.42 (0) 
LLETZ  1 516 31/258 (12.0) 17/258 (6.6) 1.82 [1.04 to 3.21] N/E (N/E) 
Excision NOS  3 1922 104/961 (10.8) 72/961 (7.5) 1.46 [0.89 to 2.39] 0.08 (60) 
Treatment NOS  1 124 10/62 (16.1) 5/62 (8.1) 2.00 [0.73 to 5.51] N/E (N/E) 
All Treatment types Untreated Colposcopy+/-Biopsy 13 74958 2033/23123 (8.8) 3119/51835 (6.0) 1.27 [1.14 to 1.41] <0.001 (55) 
CKC  2 265 25/107 (23.4) 18/158 (11.4) 1.76 [1.01 to 3.08] 0.83 (0) 
LC  1 177 20/105 (19.0) 9/72 (12.5) 1.52 [0.74 to 3.15] N/E (N/E) 
LLETZ  9 39249 877/10441 (8.4) 1511/28808 (5.2) 1.33 [1.11 to 1.6] 0.02 (55) 
LA  2 3326 115/1228 (9.4) 182/2098 (8.7) 1.05 [0.84 to 1.31] 0.45 (0) 
RD  1 2150 109/760 (14.3) 123/1390 (8.8) 1.62 [1.27 to 2.06] N/E (N/E) 
Excision NOS  5 20321 756/7933 (9.5) 961/12388 (7.8) 1.23 [1.07 to 1.41] 0.2 (33) 
Ablation NOS  2 9470 131/2549 (5.1) 315/6921 (4.6) 1.00 [0.74 to 1.36] 0.18 (45) 
All Treatment types Untreated HSIL 3 3764 364/3022 (12.0) 58/742 (7.8) 1.37 [0.85 to 2.19] 0.05 (53) 
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CKC  1 103 7/67 (10.4) 1/36 (2.8) 3.76 [0.48 to 29.39] N/E (N/E) 
NETZ  1 109 17/71 (23.9) 2/38 (5.3) 4.55 [1.11 to 18.66] N/E (N/E) 
LLETZ  1 881 55/572 (9.6) 12/309 (3.9) 2.48 [1.35 to 4.55] N/E (N/E) 
Excision NOS  2 2275 247/1955 (12.6) 38/319 (11.9) 1.06 [0.71 to 1.59] 0.24 (28) 
Ablation NOS  2 397 38/357 (10.6) 5/40 (12.5) 0.68 [0.28 to 1.68] 0.87 (0) 
Untreated population General Population 17 4359362 6261/105660 (5.9) 237203/4253702 (5.6) 1.24 [1.14 to 1.35] <0.001 (71) 
Pre-treatment pregnancies  12 3134087 3893/60543 (6.4) 176453/3073544 (5.7) 1.26 [1.08 to 1.45] 0.03 (49) 
Untreated Colposcopy+/-Biopsy  4 1046823 2310/44375 (5.2) 49646/1002448 (5.0) 1.22 [1.11 to 1.34] 0.01 (74) 
Untreated HSIL  3 178452 58/742 (7.8) 11104/177710 (6.2) 1.40 [0.94 to 2.1] 0.08 (59) 
 
CIN: cervical intraepithelial neoplasia; CKC: cold knife conisation; CT: cryotherapy; HSIL: high-grade squamous intraepithelial lesion; LA: laser ablation; LC: 
laser conisation; LLETZ: large loop excision of the transformation zone; N/E: not eligible; NETZ: needle excision of the transformation zone; NOS: not 
otherwise specified; PTB: preterm birth; RD: radical diathermy 
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Supplementary Table 2: Characteristics of included studies assessing obstetric outcomes for treated versus untreated women. 









External: matching for 
age, parity, social class, 
delivery date, singleton 
birth 
CKC 66 264 
Clinical records from 
Cardiff Cervical 
Cytology Study - Cardiff 
Birth Survey (registry) 
PTB (<37w); PTB 
(<37w)(singleton); sPTB (<37w); 
CS; ID; PrecL (<2h); ProlL (>12h); 
LBW (<2500g); PM; SB 
9 




External: matching for 
age 
CKC 48 48 
Hospital records; 
structured interviews 
LBW (<2500g) 8 






CKC 47 79 Hospital records PTB (<37w); tPTL; CS 7 







CT 115 65 Hospital records 
PTB (<36w); pPROM; CS; 
stenosis; PM 
8 
















PTB (<37w); PTB 
(<37w)(singleton); PTB 
(<37w)(multiple); PM; SB 
9 




External: matching for 
age, parity, time of 
delivery 
CKC 83 79 Hospital records 
PTB (≤37w); PTB (≤33w); PTB 
(<30w); PPH; MOH 
8 






CKC 103 720 
Hospital records 
 
PTB (<37w); cerclage 
 
8 




External: matching for 
age, race, births, 
miscarriages/TOPs 




PTB (<37w); PTB (<37w)(single); 


























































































External: matching for 
age, parity, date of 
delivery, singleton 
birth 
CKC 62 62 Hospital records 
PTB (<37w); CS; ID; IoL; 
oxytocin; analgesia; cerclage; 
PM; SB 
9 





External: matching for 
age, parity, race, year 




LA 97 97 
Hospital records; 
general practitioners 
PTB (<37w); PTB (<37w)(single); 
PTB (<37w)(repeat); pPROM; 
CS; ID; LBW (<2500g); PM 
6 




External: matching for 
age, parity, race, 










Hospital records PTB (<37w); CS; ID; ProlL(>12h) 9 




External: matching for 
age, parity, ethnic 
group 
LLETZ 40 80 
Hospital records 
 
PTB (<37w); sPTB (<37w); CS; 
ID; IoL; oxytocin; epidural; LBW 
(<2500g); NICU; PM 
9 




External: matching for 
age, parity 
LLETZ 152 152 
Hospital records 
 
PTB (<37w); CS; ID; PrecL (<2h); 
ProlL (>12h); IoL; oxytocin; 
epidural; LBW (<2500g) 
9 




External: matching for 
age, parity; regression 
for height, marital 
status, education, 
smoking, TOP - index 
pregnancy: 
hypertension, APH, 
mode of delivery 
LC 56 112 Hospital records 
PTB (≤37w); PTB 
(≤37w)(nulliparous); PTB 
(≤37w)(parous); PTB 
(≤37w)(singleton); CS; ID; APH 
9 




















































































Medical Birth Register; 
national Register of 
Hospital Discharges 









External: matching for 
age, parity, smoking 
LLETZ 78 78 
Hospital records 
 
PTB (<37w); PTB 
(<37w)(singleton); pPROM; CS; 
ID; APH; LBW (<2500g); PM 
9 




A) External: age, parity, 
partner's social class, 














PTB (<37w); PTB (<28w); PTB 
(singleton)(<37w); CS; PrecL 
(<2h); SB 
7 






LC 53 59 Hospital records 
PTB (<37w); tPTL; pPROM; CS; 
chorioamnionitis; cerclage 
7 
















mail, phone or in 
person) 
PTB (<37w) 7 





A) External: matching 











National Medical Birth 
Registry; hospital 
records 




(<37w)(repeat); CS; ID; ProlL 
(>12h); stenosis; LBW (<2500g); 
PM; SB 
8 




External: age, parity, 









LBW (<2500g); LBW (<2000g); 
LBW (<1500g); PM; SB 
8 





































































Biopsy but no 
treatment: regression 
for age 











A) External: matching 
for age, parity, marital 











PTB (<37w); PTB 











External: matching for 
age, parity 
LC 75 150 
Hospital records 
 
PTB (≤37w); PTB 
(≤37w)(D<15mm); PTB 
(≤37w)(D=15-20mm); PTB 












A) External: matching 
for age, country 
B) HSIL but no 
treatment 
Both regression for 
parity, race, smoking, 












based cancer registry); 
Birth Certificates (from 
the Department of 
Health in Washington 
state) 
PTB (<37w); PTB 









External: matching for 
age, parity, year of 
delivery 
 
LA 236 472 
Hospital records 
 
PTB (<37w); PTB (<37w)(single); 
CS; APH; LBW (<2500g); LBW 








External: matching for 






28≥ 28 Hospital records 
PTB (<37w); PTB (<37w)(single); 
PTB (<37w)(repeat); sPTB; CS; 
PrecL (<2h); LBW (<2500g); 
NICU 
9 
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Colposcopy but no 
treatment: regression 
for age, ethnicity, 
socioeconomic status, 
smoking, obstetric 
history, transfer to 
hospital, APH  
LC; LLETZ; 
LA 
652 426 Hospital records 
PTB (<37w); PTB (<37w)(single); 




(<37w)(D≥17mm); PTB (<32w); 
sPTB (<37w); pPROM 
9 




External: matching for 
age, parity 
LLETZ 119 119 Hospital records 
PTB (<37w); CS; ID; ProlL 
(>12h); IoL; oxytocin; epidural; 
pethidine 
8 




A) External: matching 










PTB (<37w); tPTL; 
chorioamnionitis; IoL; LBW 
(<2500g); PM 
9 




External: matching for 
age, parity, smoking 
status, year of delivery 
LLETZ 571 571 
Registries 
 
PTB (<37w); PTB (<37w)(single); 
PTB (<37w)(repeat); PTB 
(<37w)(singleton); PTB 
(<37w)(multiple); PTB (<34w); 
PTB (<34w)(multiple); pPROM; 
CS; IoL; oxytocin; LBW (<2500g); 
NICU; PM; SB 
9 




External: regression for 
age, gestation at USS, 








81 Hospital records 
sPTB (<37w); sPTB 
(<37w)(singleton); sPTB (<34w); 
CS; IoL; APH; LBW (<2500g); 
NICU; PM; Apgar (<7)(5min) 
8 
 




External: no matching, 
no regression 
CKC 76 29711 Hospital records 
PTB(<37w); PTB (<37w)(single); 
PTB (<37w)(singleton); 
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A) Colposcopy before 
pregnancy but no 
treatment 
B) Colposcopy during 
pregnancy but no 
treatment 
Both regression for 











Hospital records and 
registries 
PTB (<37w); PTB 
(<37w)(singleton); PTB (<32w); 
PTB (<28w); sPTB; pPROM; CS; 
ID; LBW (<2500g); PM; SB 
9 




Biopsy but no 
treatment – no 
matching, regression  
LLETZ 114 962 Hospital records 










External: regression for 
















1056855 National registers 
PTB (<37w); PTB (<28w); LBW 
(<2500g); PM 
9 





A) External: matching 
for age, parity, plurality 
B) Internal (self-
matching) 














PTB (<37w); PTB (<32w); PTB 
(<28w); pPROM; LBW (<2500g); 
LBW (<1500g); LBW (<1000g); 
PM 
8 












































































Both regression for 








PTB (<37w); PTB (<33w); PTB 
(<28w) 
9 




External: no matching, 
no regression  
LLETZ 87 18042 Hospital records PTB (≤34w) 6 
 
 








Both regression for 






National registers and 
hospital records 
PTB (<37w)(nulliparous); PTB 
(<37w)(parous) 
8 
Noehr 2009 (singletons & 






B) Biopsy but no 
treatment 
Both regression for 
age, year of delivery, 





















(<37w)(singleton); sPTB (<32w); 
sPTB (<28w) 
9 






External: regression for 
age, year of delivery, 
smoking, marital 
status, IVF 
LLETZ 166 9702 National registries 
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B) CIN3 but no 
treatment 
Both regression for 
age, smoking, 
socioeconomic status, 
























PTB (<37w); sPTB (<37w); 
pPROM; CS; LBW (<2500g); PM 
 
8 




External: matching for 
age, race, vaginal 
deliveries, gestational 








85 Hospital records 
PTB (<37w); PTB 
(<37w)(singleton); PTB (<34w); 
CS; cerclage 
8 




A) External  
B) HSIL but no 
treatment 
Both regression for 


















A) 72899  






sPTB (<37w); sPTB 
(<37w)(single); sPTB 
(<37w)(repeat); sPTB 
(<37w)(singleton); sPTB (<32w); 
sPTB (<28w); pPROM (<37w); 
pPROM (<32w); pPROM (<28w); 
LBW (<2500g); LBW (<2000g); 
LBW (<1500g); PM; PM (<37w); 
PM (<32w); PM (<28w) 
9 





External: matching for 











PTB (<37w); PTB (<37w)(single); 
PTB (<37w)(repeat); PTB 
(<37w)(singleton); PTB 
(<37w)(multiple); PTB (<34w); 
tPTL; pPROM; CS; ID; IoL; 
oxytocin; LBW (<2500g); NICU; 
PM; SB 
7 
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Both regression for 






PTB (<37w); PTB 
(nulliparous)(<37w); PTB 
(singleton)(<37w); sPTB (<37w); 
pPROM; PM; SB 
 
9 









Both regression for 
age, parity, smoking 
LLETZ 189 
A) 189  
B) 189 
Hospital records and 
registries 
PTB (<37w); PTB 
(<37w)(nulliparous); PTB 
(<37w)(parous); PTB 
(<37w)(singleton); PTB (<35w); 
PTB (<32w); CS; LBW (<2500g); 
LBW (1500g) 
9 




External: regression for 
age, birth order, year 






53 104617 Hospital records 
PTB (<34w); CS; epidural; 
cerclage; PM 
9 











58 Hospital records 
PTB (<37w); PTB 
(<37w)(D≤10mm); PTB 
(<37w)(D>10mm); CS; LBW 
(<2500g); Apgar (<7)(5min) 
7 





A) External (general 
population) 











A) 510660  
B) 7263  
C) 1173  
D) 372 
Hospital records and 
national registries 
PTB (<37w); PTB 
(<37w)(D<10mm); PTB 
(<37w)(D≥10mm); PTB 
(<37w)(singleton); PTB (<33w) 
8 




External: regression for 
parity, race, smoking, 
cervical length, PTB, 
miscarriage, LLETZ 





sPTB (<37w); sPTB (<34w) 8 
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A) External negative 
smear 
 B) Colposcopy +/- 
biopsy 
Both regression for 
age, social deprivation, 






















PTB (<37w); PTB (<37w)(single); 
PTB (<37w)(repeat); PTB 
(<37w)(singleton); PTB (<32w); 
PTB (<28w); LBW (<2500g)  
9 




External: matching for 
hospital; regression for 





























PTB (<37w); PTB 
(<37w)(D≤10mm); PTB 
(<37w)(D>10mm); PTB 
(<37w)(singleton); PTB (<32w); 
sPTB (<37w); sPTB (<32w); CS; 
LBW (<2500g) 
9 





External: matching for 






106 212 Hospital records 
PTB (<37w); PTB (<34w); tPTL; 
pPROM; chorioamnionitis; CS; 
ID; IoL; LBW (<2500g); NICU 
9 





External: matching for 
parity (nulliparous 
only), race (white only) 
 
LLETZ 406 379 
Hospital records 
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A) External with smear  
B) Biopsy but no 
treatment matching 
for age, year of 
treatment; regression 
for age, parity, race, 









A) 588  
B) 552 
Hospital records and 
structured phone 
interviews 
PTB (<37w); CS; IoL 8 





External: regression for 
age, socioeconomic 
status, marital status, 
urbanism, time to 
conception, PTB 
LLETZ 7636 658179 National registers 
PTB (<37w); PTB (<37w)(single); 

















68 Hospital records 
PTB (<37w); PTB (<37w)(single); 
PTB (<34w); pPROM; CS; PrecL 
(<2h); ProlL (>12h); LBW 
(<2500g); Apgar (<7)(1min) 
8 



















PTB (<37w); PTB (<37w)(single); 
PTB (<37w)(repeat); PTB 
(<33w); pPROM; CS; ID; LBW 
(<2500g) 
9 




External: matching for 




LLETZ 7 21 
Hospital records 
 
sPTB (<36w)(multiple) 8 
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External: regression for 
age, parity, race, PTB, 













766 Hospital records 








Biopsy but no 
treatment: matching 
for age, parity, 
smoking 
LLETZ 278 278 Hospital records 
PTB (<37w); PTB 
(<37w)(singleton); PTB (<34w); 
sPTB; pPROM; CS; ID; LBW 
(<2500g); NICU  
9 




External: matching for 
age, parity, obstetric 
history 
CKC 15 24 Hospital records PTB (<37w); pPROM; NICU  9 


















Hospital records and 
postal questionnaires 
 
PTB (<37w); PTB (<37w)(single) 8 




A) Cytology/biopsy but 
no treatment: 






A) 1129  
B) 598 
Hospital records and 
structured phone 
interviews 
sPTB (<37w); sPTB 
(<37w)(singleton); sPTB (<34w) 
9 




External: matching for 
age, parity, smoking 
Conization 
NOS 
135 135 Hospital records 
PTB (<37w); PTB 
(<37w)(singleton); CS 
9 
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 *Numbers refer to women or pregnancies 
APH: antepartum haemorrhage; BMI: body mass index; CC: cold coagulation; CIN: cervical intraepithelial neoplasia; CKC: cold knife conisation; 
CS: caesarean section; CT: cryotherapy; D: depth; HSIL: high-grade squamous intraepithelial lesion; ID: instrumental deliveries 
(ventouse/forceps); IoL: induction of labour; LA: laser ablation; LBW: low birthweight; LC: laser conisation; LLETZ: large loop excision of the 
transformation zone; MOH: massive obstetric haemorrhage; NETZ: needle excision of the transformation zone; NICU: neonatal intensive care 
unit admission; NOS: not otherwise specified; PM: perinatal mortality; PPH: postpartum haemorrhage; pPROM: preterm premature rupture of 
membranes; PreL: precipitous labour; ProlL: prolonged labour; PTB: preterm birth; RD: radical diathermy; SB: stillbirth; sPTB: spontaneous 
preterm birth; (s)PTB (single): (spontaneous) preterm birth (single cone); (s)PTB (repeat): (spontaneous) preterm birth (repeat cones); (s)PTB 
(singleton): (spontaneous) preterm birth (singleton pregnancies); (s)PTB (multiple): (spontaneous) preterm birth (multiple pregnancies); TOP: 
termination of pregnancy; tPTL: threatened preterm labour; USS: ultrasound scan; 
 





B) Women with 
untreated dysplasia 
Both regression for 













PTB (<37w); PTB 
(<37w)(singleton) 
9 
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Supplementary Table 3: Newcastle-Ottawa quality assessment of the included studies 
 
  Selection Comparability Outcome 
Reference Score 
Representativeness of 
the exposed cohort 






that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohorts on the basis of 








follow up of 
cohorts 
Jones 1979 9 
*Truly representative 
of the average 
pregnant woman with 
a previous history of 












for age, parity, social 
class, date of delivery 





follow up - 
retrospective 
Weber 1979 8 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 


















Buller 1982 7 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 














lost to follow-up 
– no description 





representative of the 
average pregnant 
woman with a previous 
history of treatment 
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  Selection Comparability Outcome 
Reference Score 
Representativeness of 
the exposed cohort 






that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohorts on the basis of 














of the average 
pregnant woman with 
a previous history of 

























representative of the 
average pregnant 
woman with a previous 
history of treatment 

















follow up - 
retrospective 
Moinian 1982 8 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 




















representative of the 
average pregnant 
woman with a previous 
history of treatment 

















lost to follow-up 
– no description 





of the average 
pregnant woman with 
a previous history of 











for age and parity 
*Record linkage 
(questionnaires for a 























follow up - 
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  Selection Comparability Outcome 
Reference Score 
Representativeness of 
the exposed cohort 






that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohorts on the basis of 








follow up of 
cohorts 
average pregnant 
woman with a previous 
history of treatment 












representative of the 
average pregnant 
woman with a previous 
history of treatment 







Hospital case notes 





for age, parity, race, 
year of delivery and 
singleton pregnancy 
 
Hospital case notes 










representative of the 
average pregnant 
woman with a previous 
history of treatment 











for age, parity, race, 
duration of pregnancy 












representative of the 
average pregnant 
woman with a previous 
history of treatment 























representative of the 
average pregnant 
woman with a previous 
history of treatment 


















Hagen 1993 9 
*Somewhat 









for age and parity; 




*Subjects lost to 
follow up (1.7%) 
unlikely to 
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  Selection Comparability Outcome 
Reference Score 
Representativeness of 
the exposed cohort 






that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohorts on the basis of 








follow up of 
cohorts 
woman with a previous 
history of treatment 




maternal height, marital 
status, level of 
education, smoking, 
previous TOP, and, in 





haemorrhage and the 






of the average 
pregnant woman with 
a previous history of 
treatment for CIN in 
the community 
*A) External: 










A) External: no 










Braet 1994 9 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 























representative of the 
average pregnant 
woman with a previous 
history of treatment 
for CIN in the 
community 
*A) External: 











**A) External: matching 
for maternal age, parity, 
husband’s or partner's 










34.7% did not 
respond to the 
questionnaire – 
no description of 
those lost 
Sagot 1995 7 *Somewhat *Internal (pre- *Secure record - *Yes *Internal (pre- *Record linkage *Yes - Inadequate: 
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  Selection Comparability Outcome 
Reference Score 
Representativeness of 
the exposed cohort 






that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohorts on the basis of 








follow up of 
cohorts 
representative of the 
average pregnant 
woman with a previous 
history of treatment 




hospital records treatment pregnancies) retrospective 21.6% could not 
be recontacted – 
no description of 
those lost 
Spitzer 1995 7 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 


















47.9% lost to 
follow-up – no 
description of 
those lost 
Bekassy 1996 8 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 
for CIN in the 
community 
A) External: 







**A) External: matching 








follow up - 
retrospective 
Forsmo 1996 8 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 
for CIN in the 
community 
*drawn from a 
same area & 







for age, parity and place 
of delivery 
Self-report & record 












representative of the 
average pregnant 
woman with a previous 
history of treatment 


















29.7% did not 
respond -  no 
description of 
those lost 
Raio 1997 9 
*Somewhat 
representative of the 
*A) External: 




**A) External: matching  




*Subjects lost to 
follow-up 
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  Selection Comparability Outcome 
Reference Score 
Representativeness of 
the exposed cohort 






that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohorts on the basis of 








follow up of 
cohorts 
average pregnant 
woman with a previous 
history of treatment 








status, social class, 










representative of the 
average pregnant 
woman with a previous 
history of treatment 






















of the average 
pregnant woman with 
a previous history of 









cancer registry and 
birth certificates 
*Yes 
**A) External: matching 
for age and country of 
origin 
B) Women with 
untreated HSIL: no 
matching 
Both had regression 
analysis for parity, race, 
maternal smoking, 
marital status and 











representative of the 
average pregnant 
woman with a previous 
history of treatment 
















*Subjects lost to 
follow-up 
(16.5%) unlikely 





representative of the 
average pregnant 
woman with a previous 










for age, parity, smoking, 
multiple pregnancies 






follow up - 
retrospective 
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  Selection Comparability Outcome 
Reference Score 
Representativeness of 
the exposed cohort 






that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohorts on the basis of 








follow up of 
cohorts 
for IA1 cervical 
carcinoma in the 
community 
 
Sadler 2004 9 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 












analysis for age, 
ethnicity, 
socioeconomic status, 
smoking in pregnancy, 
previous obstetric 











Tan 2004 8 
*Somewhat 
representative of the 
average woman with 






















retrieval of data 
Acharya 2005 9 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 
for CIN in the 
community 
*A) External: 












**A) External: matching 
for age, parity, date of 











Samson 2005 9 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 










for age, parity, smoking 
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  Selection Comparability Outcome 
Reference Score 
Representativeness of 
the exposed cohort 






that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohorts on the basis of 








follow up of 
cohorts 
community 
Crane 2006 8 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 







no description *Yes 
**External: regression 
analysis for maternal 
age, gestational age at 
the time of transvaginal 
ultrasonography, parity, 
smoking, antepartum 
bleeding after 20 weeks 









Klaritsch 2006 7 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 







*Secure record - 
hospital records 
*Yes 
External: no matching, 











representative of the 
average pregnant 
woman with a previous 
history of treatment 











colposcopy but no 
treatment: regression 
analysis for for age, 
illicit drug use during 
pregnancy, delivery at 
the RWH, marital 
status, maternal 
medical condition, 
previous TOP, previous 
miscarriage, previous 
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  Selection Comparability Outcome 
Reference Score 
Representativeness of 
the exposed cohort 






that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohorts on the basis of 








follow up of 
cohorts 
Himes 2007 8 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 











colposcopic biopsy but 
no treatment – no 












of the average 
pregnant woman with 
a previous history of 



















Sjoborg 2007 8 
*Truly representative 
of the average 
pregnant woman with 
a previous history of 
treatment for CIN in 
the community 
*A) External: 







*Secure record – 
hospital records 
*Yes 
**A) External: matching 




Both had  regression 
analysis for smoking, 






of the women 
did not respond 
or did not give 
their consent – 






of the average 
pregnant woman with 
a previous history of 
*A) External: 
drawn from the 
same 
community as 
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  Selection Comparability Outcome 
Reference Score 
Representativeness of 
the exposed cohort 






that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohorts on the basis of 








follow up of 
cohorts 







analysis for age and 
birth order 
 
Parikh 2008 6 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 







No description *Yes 
External: No matching, 




*Subjects lost to 
follow-up 
(10.3%) unlikely 





representative of the 
average pregnant 
woman with a previous 
history of treatment 




















Both had regression 













of the average 
pregnant woman with 
a previous history of 











B) Women with biopsy 
but no treatment 
Both had regression 
analysis for age, year of 
delivery, smoking 
during pregnancy and 












of the average 
pregnant woman with 
a previous history of 











analysis for age, year of 
delivery, smoking 
during pregnancy, 
marital status during 
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  Selection Comparability Outcome 
Reference Score 
Representativeness of 
the exposed cohort 






that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohorts on the basis of 














of the average 
pregnant woman with 
a previous history of 












B) Women with 
untreated CIN 3 
Both had regression 
analysis for maternal 
age at delivery, 
smoking, 
socioeconomic status, 













not known – no 
description of 
those lost 
Fischer 2010 8 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 







No description *Yes 
**External: regression 
analysis for age, race, 
the number of prior 
vaginal deliveries at ≥20 
weeks and gestational 
age at the time of 
cervical sonography 
*Record linkage *Yes 
*Complete 
follow-up 
Ortoft 2010 9 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 
for CIN in the 
community 
*A) External 
B) Women with 
untreated HSIL 
Both were 







*Secure record – 
national registries 
*Yes 
** A) External 
 B) Women with 
untreated HSIL  
Both had regr ssion 
analysis for age, parity, 
smoking status, 




*Record linkage (but 
questionnaires for 













representative of the 
average pregnant 
woman with a previous 
history of treatment 
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  Selection Comparability Outcome 
Reference Score 
Representativeness of 
the exposed cohort 






that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohorts on the basis of 








follow up of 
cohorts 
community 
Werner 2010 9 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 
for CIN in the 
community 
*A) External: 












**A) External  
B) Internal (pre-
treatment pregnancies) 
Both had regression 








Andia 2011 9 
*Truly representative 
of the average 
pregnant woman with 
a previous history of 
treatment for CIN in 
the community 
*A) External: 








*Secure record – 
hospital records 
*Yes 
**A) External  
B) Internal (pre-
treatment pregnancies) 
Both had regression 












representative of the 
average pregnant 
women with a previous 
history of treatment 











analysis for age, birth 
order, year of delivery, 










Lima 2011 7 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 







*Secure record – 
hospital records 
*Yes 









2012 (& 2014) 
8 
*Somewhat 















29.9% lost to 
follow-up 
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  Selection Comparability Outcome 
Reference Score 
Representativeness of 
the exposed cohort 






that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohorts on the basis of 








follow up of 
cohorts 
woman with a previous 
history of treatment 
for CIN in the 
community 









C/D) Internal controls 
Regression analysis for 
age parity and study 
site for a variant of the 
groups that we used 
because of 
unknown 
gestational age – 
no description of 
those lost 
Poon 2012 8 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 











analysis for parity, race, 
smoking, cervical 
length, previous 
delivery at term, 
previous PTB, previous 
miscarriage and 
previous LLETZ (for the 







Reilly 2012 9 
*Truly representative 
of the average 
pregnant woman with 
a previous history of 












B) Women with 
colposcopy +/- punch 
biopsy 
Both had regression 
analysis for maternal 
age at birth, social 
deprivation, smoking 




conception, any history 
of a previous adverse 
pregnancy outcome 





*Subjects lost to 
follow-up 
(10.6%) unlikely 
to introduce bias 
Simoens 2012 9 
*Somewhat 
representative of the 
*Drawn from 
the same 




for admittance in the 
*Record linkage *Yes 
*Complete 
follow-up 
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  Selection Comparability Outcome 
Reference Score 
Representativeness of 
the exposed cohort 






that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohorts on the basis of 








follow up of 
cohorts 
average pregnant 
woman with a previous 
history of treatment 






checking of medical 
files 
 
same maternity ward; 
regression analysis for 








representative of the 
average pregnant 
woman with a previous 
history of treatment 











for age at delivery, 
parity, smoking, history 









Frega 2013 9 
*Truly representative 
of the average 
pregnant woman with 
a previous history of 










**External: women of 
the same parity (only 
nulliparous) and race 
(only white) 
*Record linkage *Yes 
*Subjects lost to 
follow up (4.1%) 
unlikely to 
introduce bias 
Frey 2013 8 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 







*Secure record – 
hospital records 
*Yes 
**A) External  
B) Women with punch 
biopsy 
Both had matching for 
age and year of 
treatment, and 
regression analysis for 
age, parity, race, 
maternal diabetes, 
maternal BMI, neonate 














of the average 
pregnant woman with 
a previous history of 











analysis for maternal 
age, socioeconomic 
status, marital status, 
urbanism, time since 
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  Selection Comparability Outcome 
Reference Score 
Representativeness of 
the exposed cohort 






that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohorts on the basis of 








follow up of 
cohorts 
PTBs 
Guo 2013 8 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 











colposcopic biopsy +/- 
CIN: all were non-
smokers 





representative of the 
average pregnant 
woman with a previous 
history of treatment 












*Secure record – 
hospital records 
*Yes 




Both had regression 












Selected group of users 
















PTB and cervical 












representative of the 
average pregnant 
woman (with a twin 
pregnancy) with a 
previous history of 











analysis for age, parity, 
race, history of PTB, 
history of tobacco use, 








Kitson 2014 9 
*Somewhat 
representative of the 
*Drawn from 
the same 
*Secure record – 
hospital records 
*Yes 
**Women with punch 
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  Selection Comparability Outcome 
Reference Score 
Representativeness of 
the exposed cohort 






that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohorts on the basis of 








follow up of 
cohorts 
average pregnant 
woman with a previous 
history of treatment 





age, parity and smoking retrospective 
Sozen 2014 9 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 



















Martyn 2015 8 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 







*Secure record - 
questionnaires 













Stout 2015 9 
*Somewhat 
representative of the 
average pregnant 
woman with a previous 
history of treatment 













*Secure record – 
hospital records 
*Yes 
**A) Women with 
cervical cytology/punch 
biopsy: matching for 
age, hospital site and 












*Subjects lost to 
follow up (<6%) 
unlikely to 
introduce bias 
Kirn 2015 9 
*Somewhat 
representative of the 
average pregnant 
woman with a 
previous history of 

















follow up - 
retrospective 
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  Selection Comparability Outcome 
Reference Score 
Representativeness of 
the exposed cohort 






that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohorts on the basis of 








follow up of 
cohorts 
the community 
Miller 2015 9 
*Somewhat 
representative of the 
average pregnant 
woman with a 
previous history of 












B) Women with 
untreated dysplasia. 
In both groups 
regression analysis 
adjusted for age, 
body mass index at 
delivery, 
race/ethnicity, prior 
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Supplementary Table 4: Preterm birth (<37 weeks) for treated versus treated women for various cone dimensions (depth/volume) 
Comparison Group 1 Comparison Group 2 Studies Total        
N 
Treated                              
n/N (%) 
Untreated               
n/N (%) 
Effect Estimate                                                                                   





Cone Depth        
Cone Depth ≥ 10/12mm Cone Depth ≤ 12/10mm       
All Treatment types  All Treatment types  7 6359 403/3276 (12.3) 239/3083 (7.8) 1.54 [1.31, 1.80] 0.48 (0) 
LC LC 1 64 5/23 (21.7) 1/41 (2.4) 8.91 [1.11, 71.73] N/E (N/E) 
LLETZ LLETZ 2 836 25/258 (9.7) 44/578 (7.6) 1.26 [0.74, 2.17] 0.98 (0) 
Excision NOS Excision NOS 4 5459 373/2995 (12.5) 194/2464 (7.9) 1.55 [1.31, 1.83] 0.52 (0) 
Cone Depth ≥ 15/17mm Cone Depth ≤ 17/15mm       
All Treatment types  All Treatment types  4 4275 167/1661 (10.1) 149/2614 (5.7) 1.82 [1.47, 2.26] 0.55 (0) 
LC LC 1 75 14/61 (23.0) 0/14 (0) 7.02 [0.44, 111.1] N/E (N/E) 
LLETZ LLETZ 2 3869 128/1499 (8.5) 117/2370 (4.9) 1.86 [1.36, 2.55] 0.28 (14) 
Excisional Treatment NOS Excisional Treatment NOS 1 331 25/101 (24.8) 32/230 (13.9) 1.78 [1.11, 2.84] N/E (N/E) 
Cone Depth ≥ 20mm Cone Depth ≤ 20mm       
All Treatment types  All Treatment types  3 3944 87/851 (10.2) 174/3093 (5.6) 2.79 [1.24, 6.27] 0.06 (64) 
LC LC 1 75 12/42 (28.6) 2/33 (6.1) 4.71 [1.13, 19.62] N/E (N/E) 
LLETZ LLETZ 2 3869 75/809 (9.3) 172/3060 (5.6) 2.47 [0.94, 6.51] 0.05 (74) 
Cone Depth ≥ 15/17mm Cone Depth ≤ 12/10mm       
All Treatment types All Treatment types 3 2841 153/1600 (9.6) 76/1241 (6.1) 1.70 [1.31, 2.22] 0.52 (0) 
LLETZ LLETZ 2 2624 128/1499 (8.5) 62/1125 (5.5) 1.63 [1.21, 2.19] 0.36 (0) 
Excisional Treatment NOS Excisional Treatment NOS 1 217 25/101 (24.8) 14/116 (12.1) 2.05 [1.13, 3.73] N/E (N/E) 
Cone Depth ≥ 20mm Cone Depth ≤ 12/10mm       
All Treatment types  All Treatment types  2 1934 75/809 (9.3) 62/1125 (5.5) 2.49 [0.93, 6.66] 0.08 (67) 
LLETZ LLETZ 2 1934 75/809 (9.3) 62/1125 (5.5) 2.49 [0.93, 6.66] 0.08 (67) 
Cone Depth ≥ 20mm Cone Depth ≤ 15mm       
All Treatment types  All Treatment types  3 3240 87/856 (10.2) 117/2384 (4.9) 3.07 [1.27, 7.45] 0.10 (57) 
LC LC 1 61 12/47 (25.5) 0/14 (0) 7.81 [0.49, 124.25] N/E (N/E) 
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LLETZ LLETZ 2 3179 75/809 (9.3) 117/2370 (4.9) 2.85 [1.06, 7.69] 0.05 (73) 
Cone Depth ≥ 20mm Cone Depth = 15/16-19/20mm       
All Treatment types  All Treatment types  3 1560 87/851 (10.2) 55/709 (7.8) 1.46 [0.95, 2.23] 0.33 (11) 
LC LC 1 61 12/42 (28.6) 2/19 (10.5) 2.71 [0.67, 10.96] N/E (N/E) 
LLETZ LLETZ 2 1499 75/809 (9.3) 53/690 (7.7) 1.40 [0.84, 2.36] 0.26 (22) 
Cone Depth = 11/13-15/16mm Cone Depth ≤ 12/10mm       
All Treatment types  All Treatment types  3 2600 75/1359 (5.5) 76/1241 (6.1) 0.92 [0.67, 1.25] 0.48 (0) 
LLETZ LLETZ 2 2370 57/1245 (4.6) 62/1125 (5.5) 0.83 [0.58, 1.17] 0.97 (0) 
Excisional Treatment NOS Excisional Treatment NOS 1 230 18/114 (15.8) 14/116 (12.1) 1.31 [0.68, 2.50] N/E (N/E) 
Cone Depth = 15/16-19/20mm Cone Depth ≤ 12/10mm       
All Treatment types  All Treatment types  2 1815 53/690 (7.7) 62/1125 (5.5) 1.43 [1.00, 2.04] 0.53 (0) 
LLETZ LLETZ 2 1815 53/690 (7.7) 62/1125 (5.5) 1.43 [1.00, 2.04] 0.53 (0) 
Cone Depth = 15/16-19/20mm Cone Depth ≤ 15mm       
All Treatment types All Treatment types  3 3093 55/709 (7.8) 117/2384 (4.9) 1.62 [1.18, 2.20] 0.66 (0) 
LC LC 1 33 2/19 (10.5) 0/14 (0) 3.75 [0.19, 72.49] N/E (N/E) 
LLETZ LLETZ 2 3060 53/690 (7.7) 117/2370 (4.9) 1.60 [1.17, 2.19] 0.48 (0) 
Cone Volume        
Cone Volume > 3/4cc Cone Volume < 4/3cc       
All Treatment types All Treatment types  1 278 9/60 (15.0) 16/218 (7.3) 2.04 [0.95, 4.39] N/E (N/E) 
LLETZ LLETZ 1 278 9/60 (15.0) 16/218 (7.3) 2.04 [0.95, 4.39] N/E (N/E) 
Cone Volume > 6cc Cone Volume < 6cc       
All Treatment types  All Treatment types  1 278 3/6 (50.0) 22/272 (8.1) 6.18 [2.53, 15.13] N/E (N/E) 
LLETZ LLETZ 1 278 3/6 (50.0) 22/272 (8.1) 6.18 [2.53, 15.13] N/E (N/E) 
        
*If a study had more than one comparison groups, we used external groups (external general, external untreated women that had colposcopy+/-CIN+/-biopsy, women with HSIL but no treatment) in preference to 
internal comparators (self-matching or pre-treatment pregnancies).  
CIN: cervical intraepithelial neoplasia; CKC: cold knife conisation; CT: cryotherapy; HSIL: high-grade squamous intraepithelial lesion; LA: laser ablation; LC: laser conisation; LLETZ: large loop excision of the 
transformation zone; N/E: not eligible; NETZ: needle excision of the transformation zone; NOS: not otherwise specified; PTB: preterm birth; RD: radical diathermy 
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Supplementary Table 5: Preterm birth (<37 weeks) for treated women versus untreated women according to the cone depth and the 
comparison group used 
 
Treated Group  Untreated Group Studies Total        
N 
Treated                              
n/N (%) 
Untreated                             
n/N (%) 
Effect Estimate                                                                     






Cone Depth        
Cone Depth ≤ 12/10mm        
All Treatment types  Untreated External 6 1026243 271/3886 (7.0) 51295/1022357 (5.0) 1.64 [1.11, 2.42] 0.003 (72) 
 Untreated Internal 2 3550 174/2348 (7.4) 99/1202 (8.2) 0.90 [0.71, 1.14] 0.86 (0) 
 Untreated Colposcopy+/-Biopsy 4 43145 249/3548 (7.0) 1966/39597 (5.0) 1.11 [0.85, 1.43] 0.09 (54) 
Cone Depth ≥ 10/12mm        
All Treatment types Untreated External 6 1027812 511/5455 (9.4) 51295/1022357 (5.0) 1.96 [1.66, 2.32] 0.14 (40) 
 Untreated Internal 2 3944 321/2742 (11.7) 99/1202 (8.2) 2.05 [0.56, 7.48] 0.16 (50) 
 Untreated Colposcopy+/-Biopsy 4 45275 544/5678 (9.6) 1966/39597 (5.0) 1.52 [1.37, 1.68] 0.36 (6) 
Cone Depth ≤ 17/15mm        
All Treatment types Untreated External 2 513145 101/2154 (4.7) 17113/510991 (3.3) 1.40 [1.16, 1.70] 0.61 (0) 
 Untreated Colposcopy+/-Biopsy 3 34934 149/2600 (5.7) 1380/32334 (4.3) 1.17 [0.98, 1.39] 0.42 (0) 
Cone Depth ≥ 15/17mm        
All Treatment types Untreated External 2 512503 133/1512 (8.8) 17113/510991 (3.3) 3.04 [1.62, 5.73] 0.12 (59) 
 Untreated Colposcopy+/-Biopsy 3 33934 153/1600 (9.6) 1380/32334 (4.3) 2.30 [1.57, 3.35] 0.09 (59) 
Cone Depth ≤ 20mm        
All Treatment types Untreated External 2 513814 152/2823 (5.4) 17113/510991 (3.3) 1.60 [1.37, 1.87] 0.79 (0) 
 Untreated Colposcopy+/-Biopsy 2 34968 172/3060 (5.6) 1328/31908 (4.2) 1.52 [0.92, 2.51] 0.14 (54) 
Cone Depth ≥ 20mm        
All treatment types Untreated External 2 511834 84/843 (10/0) 17113/510991 (3.3) 3.63 [1.67, 7.90] 0.07 (69) 
 Untreated Colposcopy+/-Biopsy 2 32717 75/809 (9.3) 1328/31908 (4.2) 4.32 [0.93, 20.03] 0.01 (87) 
Cone Depth = 10/13-15/16mm        
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All Treatment types Untreated External 1 511959 49/1118 (4.4) 17106/510841 (3.3) 1.31 [0.99, 1.72] N/E (N/E) 
 Untreated Colposcopy+/-Biopsy 3 33693 75/1359 (5.5) 1380/32334 (4.3) 1.14 [0.90, 1.44] 0.49 (0) 
Cone Depth = 15-16/19-20mm        
All Treatment types Untreated External 2 511660 49/669 (7.3) 17113/510991 (3.3) 2.16 [1.65, 2.84] 0.96 (0) 
 Untreated Colposcopy+/-Biopsy 2 32598 53/690 (7.7) 1328/31908 (4.2) 2.38 [1.04, 5.42] 0.08 (66) 
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Supplementary Table 6: Maternal outcomes other than preterm birth comparing cervical treatment techniques to no treatment*. 
Maternal Outcomes 
 
Studies Total        N Treated                             
n/N (%) 
Untreated                             
n/N (%) 
Effect Estimate                                                  





sPTB        
sPTB (<37w)       
All Treatment types 14 1024731 1181/16849 (7.0) 37257/1007882 (3.7) 1.76 [1.47, 2.11] <0.00001 (76) 
CKC 3 7320 22/154 (14.3) 291/7166 (4.1) 3.53 [2.05, 6.05] 0.38 (0) 
LC 2 222 7/112 (6.3) 7/110 (6.4) 1.40 [0.51, 3.81] 0.70 (0) 
NETZ 1 7399 17/71 (23.9) 301/7328 (4.1) 5.83 [3.80, 8.95] N/E (N/E) 
LLETZ 11 773123 798/10890 (7.3) 25998/762233 (3.4) 1.60 [1.22, 2.08] <0.00001 (77) 
LA 1 356 8/208 (3.8) 6/148 (4.1) 0.95 [0.34, 2.68] N/E (N/E) 
CT 1 58 1/36 (2.8) 0/22 (0) 1.86 [0.08, 43.87] N/E (N/E) 
Excisional Treatment NOS 2 95985 115/1115 (10.3) 5453/94870 (5.7) 1.70 [1.17, 2.46] 0.29 (9) 
Ablative Treatment NOS 2 134720 121/2312 (5.2) 5071/132408 (3.8) 1.42 [1.20, 1.70] 0.51 (0) 
Treatment NOS 1 5548 92/1951 (4.7) 130/3597 (3.6) 1.30 [1.00, 1.69] N/E (N/E) 
sPTB (<34/32w)       
All Treatment types 7 655675 225/12486 (1.8) 3787/643189 (0.6) 2.63 [1.91, 3.62] 0.01 (58) 
CKC 2 6990 2/88 (2.3) 47/6902 (0.7) 4.38 [1.08, 17.65] N/E (N/E) 
NETZ 1 7399 5/71 (7.0) 49/7328 (0.7) 10.53 [4.33, 25.65] N/E (N/E) 
LLETZ 6 530985 197/10176 (1.9) 3113/520809 (0.6) 2.37 [1.82, 3.08] 0.16 (37) 
CT 1 58 1/36 (2.8) 0/22 (0) 1.86 [0.08, 43.87] N/E (N/E) 
Excisional Treatment NOS 1 264 3/88 (3.4) 0/176 (0) 13.92 [0.73, 266.6] N/E (N/E) 
Ablative Treatment NOS 1 109979 17/2027 (0.8) 578/107952 (0.5) 1.57 [0.97, 2.53] N/E (N/E) 
sPTB (<28w)       
All Treatment types 2 626670 65/10917 (0.6) 1523/615753 (0.2) 3.18 [1.64, 6.16] 0.02 (68) 
CKC 1 6956 1/67 (1.5) 19/6889 (0.3) 5.41 [0.74,39.84] N/E (N/E) 
NETZ 1 7399 3/71 (4.2) 21/7328 (0.3) 14.74 [4.5, 48.32] N/E (N/E) 
LLETZ 2 502336 55/8752 (0.6) 1221/493584 (0.2) 2.57 [1.96, 3.36] 0.66 (0) 
Ablative Treatment NOS 1 109979 6/2027(0.3) 262/107952 (0.2) 1.22 [0.54, 2.74] N/E (N/E) 
Threatened PTB       
All Treatment types 5 903 31/340 (9.1) 18/563 (3.2) 2.44 [1.37, 4.33] 0.43 (0) 
CKC 1 126 5/47 (10.6) 6/79 (7.6) 1.40 [0.45, 4.34] N/E (N/E) 
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LC 1 112 7/53 (13.2) 5/59 (8.5) 1.56 [0.53, 4.62] N/E (N/E) 
LLETZ 1 237 4/79 (5.1) 2/158 (1.3) 4.00 [0.75, 21.37] N/E (N/E) 
Excisional Treatment NOS 2 428 15/161 (9.3) 5/267(1.9) 4.51 [1.68, 12.06] 0.52 (0) 
pPROM       
pPROM (<37w)       
All Treatment types 21 477011 485/7903 (6.1) 15970/469108 (3.4) 2.36 [1.76, 3.17] <0.00001 (79) 
CKC 4 36733 28/194 (14.4) 930/36539 (2.5) 4.11 [2.05, 8.25] 0.12 (49) 
LC 4 635 43/292 (14.7) 25/343 (7.3) 1.89 [0.97, 3.66] 0.21 (34) 
NETZ 1 7279 14/71 (19.7) 161/7208 (2.2) 8.83 [5.39, 14.46] N/E (N/E) 
LLETZ 8 302974 124/2428 (5.1) 7619/300546 (2.5) 2.15 [1.48, 3.12] 0.09 (43) 
LA 2 548 18/307 (5.9) 9/241 (3.7) 1.62 [0.74, 3.55] 0.64 (0) 
CT 1 180 4/115 (3.5) 2/65 (3.1) 1.13 [0.21, 6.00] N/E (N/E) 
Excisional Treatment NOS 5 98372 162/2260 (7.2) 5680/96112 (5.9) 2.66 [1.13, 6.24] <0.0001 (84) 
Ablative Treatment NOS 1 24742 25/285 (8.8) 1458/24457 (6.0) 1.47 [1.01, 2.15] N/E (N/E) 
Treatment NOS 1 5548 67/1951 (3.4) 86/3597 (2.4) 1.44 [1.05, 1.97] N/E (N/E) 
pPROM (<32w)       
All Treatment types 1 72788 12/710 (1.7) 202/72078 (0.3) 8.30 [2.03, 33.98] 0.01 (78) 
CKC 1 6842 1/67 (1.5) 19/6775 (0.3) 5.32 [0.72, 39.19] N/E (N/E) 
NETZ 1 7279 5/71 (7.0) 20/7208 (0.3) 25.38 [9.8, 65.74] N/E (N/E) 
LLETZ 1 58667 6/572 (1.0) 163/58095 (0.3) 3.74 [1.66, 8.41] N/E (N/E) 
pPROM (<28w)       
All Treatment types 1 72788 4/710 (0.6) 70/72078 (0.1) 9.09 [1.04, 7.18] 0.03 (72) 
CKC 1 6842 0/67 (0) 7/6775 (0.1) 6.64 [0.38, 115.2] N/E (N/E) 
NETZ 1 7279 3/71 (4.2) 7/7208 (0.1) 43.51 [11.48, 164.9] N/E (N/E) 
LLETZ 1 58667 1/572 (0.2) 56/58095 (0.1) 1.81 [0.25, 13.08] N/E (N/E) 
Chorioamnionitis       
All Treatment types 4 29198 11/314 (3.5) 316/28884 (1.1) 3.43 [1.36, 8.64] 0.74 (0) 
CKC 1 28531 2/76 (2.6) 313/28455 (1.1) 2.39 [0.61, 9.43] N/E (N/E) 
LC 1 112 1/53 (1.9) 0/59 (0) 3.33 [0.14, 80.11] N/E (N/E) 
LLETZ 1 237 5/79 (6.3) 1/158 (0.6) 10.00 [1.19, 84.15] N/E (N/E) 
Excisional Treatment NOS 1 318 3/106 (2.8) 2/212 (0.9) 3.00 [0.51, 17.68] N/E (N/E) 
Mode of Delivery       
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Caeserean Section       
All Treatment types 36 272360 1784/8942 (20.0) 46929/263418 (17.8) 1.06 [0.98, 1.14] 0.15 (19) 
CKC 6 30462 54/308 (17.5) 3698/30154 (12.3) 1.24 [0.91, 1.68] 0.36 (9) 
LC 5 1038 57/445 (12.8) 63/593 (10.6) 1.38 [0.90, 2.11] 0.23 (29) 
LLETZ 14 5436 509/2363 (21.5) 672/3073 (21.9) 1.04 [0.94, 1.15] 0.71 (0) 
LA 4 1258 50/510 (9.8) 86/748 (11.5) 0.86 [0.61, 1.20] 0.62 (0) 
CT 2 238 24/151 (15.9) 5/87 (5.7) 2.47 [1.02, 6.01] 0.32 (0) 
Excisional Treatment NOS 8 203262 622/2713 (22.9) 36670/200549 (18.3) 1.06 [0.90, 1.25] 0.06 (49) 
Ablative Treatment NOS 2 24848 71/366 (19.4) 5103/24482 (20.8) 1.38 [0.42, 4.58] 0.17 (48) 
Treatment NOS 2 5818 397/2086 (19.0) 632/3732 (16.9) 1.03 [0.78, 1.35] 0.13 (56) 
Instrumental Deliveries (ventouse/forceps)       
All Treatment types 16 9588 484/3773 (12.8) 793/815 (13.6) 0.97 [0.88, 1.08] 0.72 (0) 
CKC 2 454 10/128 (7.8) 24/326 (7.4) 1.33 [0.66, 2.70] 0.40 (0) 
LC 2 668 21/306 (6.9) 22/362 (6.1) 1.16 [0.65, 2.07] 0.66 (0) 
LLETZ 6 1418 85/689 (12.3) 98/729 (13..4) 0.89 [0.68, 1.17] 0.70 (0) 
LA 3 550 39/274 (14.2) 42/276 (15.2) 0.94 [0.62, 1.41] 0.37 (0) 
Excisional Treatment NOS 3 950 33/425 (7.8) 68/525 (13.0) 0.71 [0.46, 1.10] 0.32 (11) 
Treatment NOS 1 5548 296/1951 (15.2) 539/3597 (15.0) 1.01 [0.89, 1.15] N/E (N/E) 
Length of Labour       
Precipitous Labour (<2h)       
All Treatment types 5 1059 34/397 (8.6) 43/662 (6.5) 1.26 [0.80, 1.96] 1.00 (0) 
CKC 2 289 5/71 (7.0) 15/218 (6.9) 1.24 [0.47, 3.27] N/E (N/E) 
LLETZ 4 770 29/326 (8.9) 28/444 (6.3) 1.26 [0.76, 2.08] 1.00 (0) 
Prolonged Labour (>12 h)       
All Treatment types 7 1854 76/859 (8.8) 75/995 (7.5) 1.25 [0.92, 1.69] 0.59 (0) 
CKC 2 325 8/91 (8.8) 15/234 (6.4) 1.99 [0.89, 4.45] N/E (N/E) 
LC 1 500 11/50 (4.4) 12/50 (4.8) 0.92 [0.41, 2.04] N/E (N/E) 
LLETZ 4 673 22/341 (6.5) 23/332 (6.9) 0.96 [0.55, 1.70] 0.48 (0) 
LA 2 356 35/177 (19.8) 25/179 (14.0) 1.41 [0.88, 2.26] 0.60 (0) 
Induction of Labour       
All Treatment types 11 4668 477/1971 (24.2) 638/2697 (23.7) 1.01 [0.89, 1.15] 0.34 (10) 
CKC 2 137 14/73 (19.2) 10/64(15.6) 1.11 [0.54, 2.29] 0.75 (0) 
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LLETZ 8 4056 421/1712 (24.6) 551/2344 (23.5) 0.99 [0.82, 1.20] 0.13 (38) 
CT 1 58 6/36 (16.7) 6/22 (27.3) 0.61 [0.22, 1.66] N/E (N/E) 
Excisional Treatment NOS 2 417 36/150 (24.0) 71/267 (26.6) 0.90 [0.64, 1.28] 0.79 (0) 
Oxytocin Use       
All Treatment types 6 2006 166/978 (17.0) 180/1028 (17.5) 0.90 [0.64, 1.26] 0.04 (58) 
CKC 1 103 19/52 (36.5) 19/51 (37.3) 0.98 [0.59, 1.63] N/E (N/E) 
LLETZ 4 1804 131/882 (14.9) 144/922 (15.6) 0.76 [0.43, 1.34] 0.01 (74) 
Excisional Treatment NOS 1 99 16/44 (36.4) 17/55 (30.9) 1.18 [0.67, 2.05] N/E (N/E) 
Haemorrhage       
Antepartum Haemorrhage       
All Treatment types 4 1245 24/502 (4.8) 21/743 (2.8) 1.11 [0.40, 3.12] 0.03 (59) 
CKC 1 34 4/21 (19.0) 2/13 (15.4) 1.24 [0.26, 5.83] N/E (N/E) 
LC 1 168 4/56 (7.1) 0/112 (0.0) 17.84 [0.98, 325.7] N/E (N/E) 
LLETZ 2 277 10/153 (6.5) 15/124 (12.1) 0.52 [0.16, 1.67] 0.15 (53) 
LA 1 708 4/236 (1.7) 1/472 (0.2) 8.00 [0.90, 71.18] N/E (N/E) 
CT 1 58 2/36 (5.6) 3/22 (13.6) 0.41 [0.07, 2.25] N/E (N/E) 
Postpartum Haemorrhage (>600ml)       
All Treatment types 1 149 14/75 (18.7) 3/74 (4.1) 4.60 [1.38, 15.36] N/E (N/E) 
CKC 1 149 14/75 (18.7) 3/74 (4.1) 4.60 [1.38, 15.36] N/E (N/E) 
Massive Obstetric Haemorrhage (>1000ml)       
All Treatment types 1 149 4/75 (5.3) 1/74 (1.4) 3.95 [0.45, 34.48] N/E (N/E) 
CKC 1 149 4/75 (5.3) 1/74 (1.4) 3.95 [0.45, 34.48] N/E (N/E) 
Analgesia       
Epidural Use       
All Treatment types 5 105488 87/442 (19.7) 23205/105046 (22.1) 1.02 [0.68, 1.53] 0.02 (64) 
LLETZ 4 818 66/389 (17.0) 85/429 (19.8) 0.86 [0.64, 1.16] 0.86 (0) 
Excisional Treatment NOS 1 104670 21/53 (9.6) 23120/104617 (22.1) 1.79 [1.29, 2.50] N/E (N/E) 
Pethidine Use       
All Treatment types 2 394 61/197 (31.0) 64/197 (32.5) 0.94 [0.72, 1.24] 0.62 (0) 
LLETZ 2 394 61/197 (31.0) 64/197 (32.5) 0.94 [0.72, 1.24] 0.62 (0) 
Analgesia use NOS       
All Treatment types 1 103 17/52 (32.7) 15/51 (29.4) 1.11 [0.62, 1.98] N/E (N/E) 
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CKC 1 103 17/52 (32.7) 15/51 (29.4) 1.11 [0.62, 1.98] N/E (N/E) 
Cervical cerclage       
All Treatment types 8 141300 97/2416 (4.0) 932/138884 (0.7) 14.29 [2.85, 71.65] <0.00001 (93) 
CKC 3 30744 41/246 (16.7) 71/30498 (0.2) 31.42 [2.32, 426.22] 0.07 (62) 
LC 1 112 6/53 (11.3) 1/59 (1.7) 6.68 [0.83, 53.69] N/E (N/E) 
LLETZ 1 56 5/28 (17.9) 0/28 (0) 11.00 [0.64, 189.96] N/E (N/E) 
Excisional Treatment NOS 2 104840 18/138 (13.0) 837/104702 (0.8) 42.45 [28.99, 62.16] N/E (N/E) 
Treatment NOS 1 5548 27/1951 (1.4) 23/3597 (0.6) 2.16 [1.24, 3.76] N/E (N/E) 
Cervical stenosis       
All Treatment types 2 680 2/365 (0.5) 0/315 (0.0) 2.26 [0.24, 21.59] 0.81 (0) 
LC 1 500 1/250 (0.4) 0/250 (0.0) 3.00 [0.12, 73.29] N/E (N/E) 
CT 1 180 1/115 (0.9) 0/65 (0.0) 1.71 [0.07, 41.31] N/E (N/E) 
*If a study had more than one comparison groups, we used external groups (external general, external untreated women that had colposcopy+/-CIN+/-biopsy, women with HSIL but no treatment) in preference to 
internal comparators (self-matching or pre-treatment pregnancies).  
 
CKC: cold knife conisation; CT: cryotherapy; g: grams; LA: laser ablation; LBW: low birth weight; LC: laser conisation; LLETZ: large loop excision of the transformation zone; min: minute; N/E: not eligible; NETZ: needle 
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Supplementary Table 7: Neonatal outcomes comparing cervical treatment techniques to no treatment*. 
Neonatal Outcomes Studies Total           
N 
Treated                              
n/N (%) 
Untreated                                  
n/N (%) 
Effect Estimate                                          





Birth weight       
LBW (<2500g)       
All Treatment types 30 1348206 1542/19489 (7.9) 48632/1328717 (3.7) 1.81 [1.58, 2.07] <0.00001 (63) 
CKC 5 30304 49/246 (19.9) 2308/30058 (7.7) 2.51 [1.78, 3.53] 0.79 (0) 
LC 4 786 29/336 (8.6) 30/450 (6.7) 1.76 [0.72, 4.35] 0.04 (63) 
LLETZ 12 3357 157/1605 (9.8) 83/1752 (4.7) 2.11 [1.51, 2.94] 0.13 (32) 
LA 4 1104 29/421 (6.9) 42/683 (6.1) 1.07 [0.59, 1.92] 0.29 (20) 
CT 1 58 6/36 (16.7) 1/22 (4.5) 3.67 [0.47, 28.47] N/E (N/E) 
Excisional Treatment NOS 10 823648 840/10416 (8.1) 29739/813232 (3.7) 2.01 [1.62, 2.49] <0.00001 (78) 
Ablative Treatment NOS 4 483402 220/4478 (4.9) 16140/478924 (3.4) 1.36 [1.19, 1.55] 0.88 (0) 
Treatment NOS 1 5547 212/1951 (10.9) 289/3596 (8.0) 1.35 [1.14, 1.60] N/E (N/E) 
LBW (<2000g)       
All Treatment types 3 74981 50/1053 (4.7) 788/73928 (1.1) 2.49 [0.97, 6.36] 0.01 (72) 
LC 1 181 7/51 (13.7) 4/130 (3.1) 4.46 [1.36, 14.59] N/E (N/E)  
LA 2 772 7/256 (2.7) 15/516 (2.9) 0.95 [0.39, 2.29] 0.89 (0) 
Excisional Treatment NOS 1 74028 36/746 (4.8) 769/73282 (1.0) 4.60 [3.32, 6.37] N/E (N/E) 
LBW (<1500g)       
All Treatment types 5 76836 39/1977 (2.0) 390/74859 (0.5) 3.00 [1.54, 5.85] 0.24 (26) 
LC 1 181 5/51 (9.8) 1/130 (0.8) 12.75 [1.53, 106.44] N/E (N/E) 
LLETZ 1 378 3/189 (1.6) 0/189 (0) 7.00  [0.36, 134.59] N/E (N/E) 
LA 2 772 2/256 (0.8) 7/516 (1.4) 0.68 [0.16, 2.80] 0.97 (0) 
Excisional Treatment NOS 2 75505 29/1481 (2.0) 382/74024 (0.5) 3.34 [2.02, 5.54] 0.61 (0) 
LBW (<1000g)       
All Treatment types 2 2185 11/971 (1.1) 4/1214 (0.3) 2.09 [0.06, 74.71] 0.05 (75) 
LA 1 708 0/236 (0) 3/472 (0.6) 0.29 [0.01, 5.50] N/E (N/E) 
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Excisional Treatment NOS 1 1477 11/735 (1.5) 1/742 (0.1) 11.10 [1.44, 85.79] N/E (N/E) 
NICU Admission       
All Treatment types 8 2533 155/1226 (12.6) 119/1307 (9.1) 1.44 [1.14, 1.82] 0.64 (0) 
CKC 2 47 6/35 (17.1) 6/12 (50.0) 0.60 [0.04, 8.73] N/E (N/E) 
LLETZ 5 1994 110/991 (11.1) 81/1003 (8.1) 1.42 [1.01, 1.99] 0.36 (8) 
CT 1 58 4/36 (11.1) 1/22 (4.5) 2.44 [0.29, 20.49] N/E (N/E) 
Excisional Treatment NOS 2 434 35/164 (21.3) 31/270 (11.5) 1.76 [1.13, 2.75] 0.85 (0) 
Perinatal Mortality       
Perinatal mortality overall       
All Treatment types 23 1659433 149/15817 (0.9) 11687/1643616 (0.7) 1.51 [1.13, 2.03] 0.04 (36) 
CKC 7 50588 16/573 (2.8) 945/50015 (1.9) 1.46 [0.83, 2.57] 0.93 (0) 
LC 3 906 6/376 (1.6) 5/530 (0.9) 1.89 [0.26, 13.87] 0.10 (63) 
NETZ 1 7399 3/71 (4.2) 31/7328 (0.4) 9.99 [3.13, 31.92] N/E (N/E) 
LLETZ 7 302271 17/1925 (0.9) 2430/300346 (0.8) 1.53 [0.88, 2.67] 0.93 (0) 
LA 2 258 1/117 (0.9) 0/141 (0) 3.00 [0.12, 72.74] N/E (N/E) 
CT 2 238 0/151 (0) 1/87 (1.1) 0.19 [0.01, 4.59] N/E (N/E) 
Excisional Treatment NOS 5 820028 63/6792 (0.9) 5427/813236 (0.7) 1.85 [1.02, 3.36] 0.08 (56) 
Ablative Treatment NOS 2 472197 16/3861 (0.4) 2798/468336 (0.6) 0.69 [0.42, 1.13] 0.77 (0) 
Treatment NOS 1 5548 27/1951 (1.4) 50/3597 (1.4) 1.00 [0.63, 1.58] N/E (N/E) 
Perinatal Mortality (<37w)       
All Treatment types 1 73992 6/710 (0.8) 98/73282 (0.1) 9.40 [2.01, 43.89] 0.06 (65) 
CKC 1 6956 0/67 (0) 9/6889 (0.1) 5.33 [0.31, 90.71] N/E (N/E) 
NETZ 1 7399 3/71 (4.2) 10/7328 (0.1) 30.96 [8.71, 110.13] N/E (N/E) 
LLETZ 1 59637 3/572 (0.5) 79/59065 (0.1) 3.92 [1.24, 12.38] N/E (N/E) 
Perinatal Mortality (<32w)       
All Treatment types 1 73992 6/710 (0.8) 71/73282 (0.1) 12.77 [2.51, 64.99] 0.05 (67) 
CKC 1 6956 0/67 (0) 7/6889 (0.1) 6.75 [0.39, 117.10] N/E (N/E) 
NETZ 1 7399 3/71 (4.2) 7/7328 (0.1) 44.23 [11.67, 167.61] N/E (N/E) 
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LLETZ 1 59637 3/572 (0.5) 57/59065 (0.1) 5.43 [1.71, 17.30] N/E (N/E) 
Perinatal Mortality (<28w)       
All Treatment types 1 73992 5/710 (0.7) 57/73282 (0.1) 13.76 [2.37, 79.89] 0.05 (67) 
CKC 1 6956 0/67 (0) 5/6889 (0.1) 9.21 [0.51, 164.95] N/E (N/E) 
NETZ 1 7399 3/71 (4.2) 6/7328 (0.1) 51.61 [13.17, 202.29] N/E (N/E) 
LLETZ 1 59637 2/572 (0.3) 46/59065 (0.1) 4.49 [1.09, 18.45] N/E (N/E) 
Stillbirth       
All Treatment types 12 249855 28/3920 (0.7) 1376/245935 (0.6) 0.98 [0.63, 1.52] 0.80 (0) 
CKC 3 935 5/325 (1.5) 5/610 (0.8) 1.61 [0.48, 5.40] 0.66 (0) 
LC 2 725 1/325 (0.3) 3/400 (0.8) 0.33 [0.03, 3.18] N/E (N/E) 
LLETZ 4 242473 7/1244 (0.6) 1332/241229 (0.6) 1.42 [0.62, 3.26] 0.84 (0) 
LA 1 64 0/20 (0) 0/44 (0) N/E N/E (N/E) 
Treatment NOS 1 5548 15/1951 (0.8) 36/3597 (1.0) 0.77 [0.42, 1.40] N/E (N/E) 
Excisional Treatment NOS 1 110 0/55 (0) 0/55 (0) N/E N/E (N/E) 
Apgar score       
Apgar score (≤5)(1min)       
All Treatment types 1 225 2/75 (2.7) 7/150 (4.7) 0.57 [0.12, 2.68] N/E (N/E) 
LC 1 225 2/75 (2.7) 7/150 (4.7) 0.57 [0.12, 2.68] N/E (N/E) 
Apgar score (<7)(1min)       
All Treatment types 1 152 2/84 (2.4) 3/68 (4.4) 0.63 [0.07, 5.71] 0.24 (28) 
LLETZ 1 87 0/48 (0) 2/39 (5.1) 0.16 [0.01, 3.30] N/E (N/E) 
CKC 1 65 2/36 (5.6) 1/29 (3.4) 1.61 [0.15, 16.90] N/E (N/E) 
Apgar score (<7)(5min)       
All Treatment types 2 297 4/159 (2.5) 3/138 (2.2) 0.82 [0.19, 3.59] 0.80 (0) 
CKC 1 32 0/20 (0) 0/12 (0) N/E N/E (N/E) 
LLETZ 1 120 3/74 (4.1) 2/46 (4.3) 0.93 [0.16, 5.37] N/E (N/E) 
CT 1 58 1/36 (2.8) 1/22 (4.5) 0.61 [0.04, 9.28] N/E (N/E) 
Excisional Treatment NOS 1 87 0/29 (0) 0/58 (0) N/E N/E (N/E) 
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*If a study had more than one comparison groups, we used external groups (external general, external untreated women that had colposcopy+/-CIN+/-biopsy, women with HSIL but no treatment) in preference to 
internal comparators (self-matching or pre-treatment pregnancies).  
 
CKC: cold knife conisation; CT: cryotherapy; g: grams; LA: laser ablation; LBW: low birth weight; LC: laser conisation; LLETZ: large loop excision of the transformation zone; min: minute; N/E: not eligible; NETZ: needle 
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